Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMS) and antibody checkpoint inhibitors
Combining SGRMs with antibody checkpoint inhibitors addresses the immunosuppressive effects of cortisol in ACC, enhancing treatment efficacy by restoring immune cell signaling and infiltration, thereby reducing tumor burden.
Patent Information
- Application Number
- JP2024135686
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-15
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
AI Technical Summary
Existing treatments for adrenocortical carcinoma (ACC) are limited by the immunosuppressive effects of cortisol excess, which reduces the efficacy of antibody checkpoint inhibitors, and there is a need for more effective therapies to enhance their effectiveness.
Combining selective glucocorticoid receptor modulators (SGRMs) with antibody checkpoint inhibitors to counteract the immunosuppressive effects of cortisol excess in ACC patients, thereby restoring T cell and natural killer (NK) cell signaling pathways and increasing their infiltration into tumors.
This combination therapy effectively reduces ACC tumor burden, restores immune cell signaling pathways, and enhances the response to antibody checkpoint inhibitors in patients with cortisol excess.
Smart Images

Figure 2024164083000001_ABST
Abstract
Description
[Technical field]
[0001] The adrenal glands are the natural source of the glucocorticoid (GC) cortisol. Cortisol is produced and secreted by the adrenal glands in response to adrenocorticotropic hormone (ACTH) secreted by the pituitary gland. Cortisol levels vary throughout the day and can be measured in blood (e.g., serum, plasma, or whole blood) and in the morning (when cortisol levels are typically highest). Cortisol levels can also be measured in urine (e.g., 24-hour urinary cortisol measurements, which allow for cortisol measurements that are less affected by the time of day sampling is performed), in saliva (e.g., midnight salivary cortisol, when cortisol levels are typically lowest), and in other body fluids (e.g., tears and sweat). Cortisol may also be measured after a dexamethasone suppression test, in which cortisol is an indicator of the response of the hypothalamic-pituitary-adrenal axis to exogenously administered glucocorticoids such as dexamethasone. [Background technology]
[0002] Elevated glucocorticoid (GC) activity, referred to as "cortisol excess" or "excess cortisol", while difficult to precisely quantify, has been linked to the pathophysiology of several cancer types. Approximately half of patients with adrenocortical carcinoma (ACC) show unequivocal clinical and biochemical evidence of systemic GC excess (GC+), presenting a unique test case for correlative evaluation of GC activity. This broad immunosuppressive effect of GCs may limit tumor immune responses and the efficacy of immune checkpoint inhibitors (ICIs).
[0003] Adrenal cortical carcinoma (ACC) limits the efficacy of antibody checkpoint inhibitors. Approximately half of patients with ACC present with systemic cortisol excess (GC+). Cortisol excess leads to disorders such as Cushing's syndrome. In addition, cortisol has immunosuppressive effects. Immunosuppression is associated with an inadequate response to checkpoint inhibitors. The specific immunosuppressive effects of cortisol in ACC are unknown; thus, the immunosuppressive effects of SGRMs in GC+ACC are unknown.
[0004] There is a need in the art to provide more effective treatments for ACC, including enhancing the effects of antibody checkpoint inhibitor treatment for ACC patients. Summary of the Invention
[0005] A multi-omics analysis of adrenocortical carcinoma (ACC) identified molecular consequences of glucocorticoid (GC) activity and assessed the rationale for combining the glucocorticoid receptor (GR) antagonist relacorilant with immune checkpoint inhibitors (ICIs) in adrenocortical carcinoma with glucocorticoid excess (GC+ACC).Applicant conducted an analysis of published data on gene transcription and GC excess (e.g., cortisol excess) in ACC tumors.
[0006] The treatment method includes administering a selective glucocorticoid receptor modulator (SGRM) and an antibody checkpoint inhibitor to an adrenocortical carcinoma (ACC) patient with cortisol excess. The patient has cortisol excess, which is when the cortisol level is above the normal range, e.g., above the upper normal cortisol level. In some embodiments, cortisol excess is identified when the patient's cortisol level is greater than about 1.5 times the normal cortisol level, or greater than about 2 times the normal cortisol level. In some embodiments, cortisol excess is identified when an irregular elevation is identified in the patient's diurnal cortisol rhythm.
[0007] The effects of excess cortisol can include, for example, an increase in the effect of cortisol on immune responses in and against tumors (e.g., immunosuppression in tumors, lymph nodes, etc.). In some embodiments, administering an SGRM in combination with an antibody checkpoint inhibitor can be effective in reducing or reversing the effects of excess cortisol in ACC patients with excess cortisol, and can be effective in reducing ACC tumor load in such patients. In some embodiments, administering an SGRM in combination with an antibody checkpoint inhibitor can be effective in reducing or reversing the effects of excess cortisol in ACC patients with excess cortisol, and can be effective in restoring T cell signaling pathways and natural killer (NK) cell signaling pathways in such patients. In some embodiments, administering an SGRM in combination with an antibody checkpoint inhibitor can be effective in reducing or reversing the effects of excess cortisol in ACC patients with excess cortisol, and can be effective in increasing infiltration of T cells and natural killer (NK) cells into ACC tumors in such patients. In certain embodiments, administering a SGRM in combination with an antibody checkpoint inhibitor may be effective in reducing or reversing the effects of excess cortisol in ACC patients with excess cortisol, and may be effective in reducing neutrophil infiltration into ACC tumors in such patients.
[0008] In some cases, the GRM (e.g., SGRM) is a non-steroidal compound comprising a fused azadecalin structure, wherein the fused azadecalin structure is as described and disclosed in U.S. Pat. No. 7,928,237 and U.S. Pat. No. 8,461,172, the entireties of which are incorporated by reference herein.
[0009] In some cases, the GRM (e.g., SGRM) is a non-steroidal compound comprising a heteroaryl ketone-fused azadecalin structure, wherein the heteroaryl ketone-fused azadecalin structure is as described and disclosed in U.S. Pat. No. 8,859,774, the entirety of which is incorporated herein by reference.
[0010] In some cases, the GRM (e.g., SGRM) is a non-steroidal compound comprising an octahydro-fused azadecalin structure, wherein the octahydro-fused azadecalin structure is as described and disclosed in U.S. Pat. No. 10,047,082, the entirety of which is incorporated herein by reference.
[0011] In some cases, the GRM (eg, an SGRM, eg, a non-steroidal SGRM) is administered orally.
[0012] The methods provide improved methods for treating adrenocortical carcinoma (ACC). The methods disclosed herein are believed to provide therapeutic benefits to ACC patients, including, for example, reduction in ACC tumor burden, restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and decreased infiltration of neutrophils into ACC tumors, as well as other therapeutic benefits. [Brief description of the drawings]
[0013] [Figure 1] Figure 1 shows the differences in transcriptional pathways in GC+ACC cases ("GC+" represents ACC patients with GC excess). Reduced expression refers to pathways that are decreased in GC+ACC cases, and increased expression refers to pathways that are increased in GC+ACC.
[0014] [Diagram 2]Figure 2 shows the abundance of specific immune cell types in ACC tumors. GC+ cases had low abundance of lymphocytes (left) and high abundance of mesenchymal stem cells and neutrophils (right).
[0015] [Figure 3A] Classification of ACC tumors by hormonal status. Among the four comparisons performed, the presence or absence of GC excess (GC+ / -) was associated with the highest number of significantly different genes in ACC (where "GC-" represents ACC patients without GC excess).
[0016] [Figure 3B] Effect of GC excess on transcription. The expression of 858 genes was found to be significantly affected by GC excess. Genes that were upregulated in GC+ cases (P < .05 and >2-fold change in expression compared to GC-) are shown on the right. Genes that were downregulated in GC+ cases are shown on the left.
[0017] [Figure 4] Effect of GC on promoter methylation. In GC+ tumors, there were significantly more genes with hypomethylation (P ≤ 0.05, Δβ < -0.2) than with hypermethylation (P ≤ 0.05, Δβ > 0.2). β value represents the percentage of methylation in a gene.
[0018] [Diagram 5]Unsupervised clustering of normalized gene expression for two KEGG pathways. Pathways shown include the T cell receptor signaling pathway and the natural killer cell-mediated cytotoxicity pathway. The top two columns show the GC and general hormone status of each tumor (black: GC+ / H+, white: GC- / H-), and the blue / red shades (shown in greyscale) show the normalized gene expression of each tumor, with darker blue corresponding to lower expression. When clustered on gene expression, GC+ cases appear on the right side of the figure, with many genes showing low expression. ("H+" represents the presence of hormones, and "H-" represents the absence of hormones.)
[0019] [Figure 6] Supervised clustering of normalized gene expression for the two KEGG pathways shown in Figure 5. In GC+ cases (clustered on the right), low gene expression predominates in these pathways (dark blue).
[0020] [Figure 7] Increased tumor mutation burden in GC+ACC. More missense and nonsense mutations were observed in GC+ cases compared with GC-.
[0021] [Figure 8] GR activity scores in different tumor types and ACC subsets. ACC showed higher GR-driven gene activity compared to other tumors, independent of hormone status (see inset).
[0022] [Figure 9] Derivation of a gene signature that distinguishes GC+ACC from GC-ACC cases using random forests. NLRP1 and ZNF683 (highlighted) were identified as significant signature components. Only signature genes above a threshold of 0.0028 are shown (where "au" represents an artificial unit of importance for each gene).
[0023] [Figure 10A] Application of the ACC gene signature to TCGA tumors. Note that data from ACC tumors are shown together in the leftmost box (indicated by a bar above the label "ACC"). Data points from ACC patients not showing GC excess (GC-) and those showing GC excess (GC+) are shown separately by arrows labeled on top of the corresponding box. Uveal melanoma (UVM) and cutaneous melanoma (SKCM) are predicted to have the highest frequency of tumors resembling GC+ACC.
[0024] [Figure 10B] Predicted frequency of tumor cases resembling GC+ACC. Uveal melanoma (UVM) and cutaneous melanoma (SKCM) are predicted to have the highest frequency of tumors resembling GC+ACC.
[0025] [Figure 11A] Effects of stimulation with IL-2, cortisol, and / or relaxorilant on isolated human NK cells in vitro. Addition of relaxorilant significantly enhanced natural killer (NK) cell activation in response to IL-2.
[0026] [Figure 11B] Effects of stimulation with IL-2, cortisol, and / or relaxorilant on isolated human NK cells in vitro. Addition of relaxorilant significantly enhanced NK cell proliferation in response to IL-2.
[0027] [Figure 12]FIG. 12A. Effect of stimulation with IL-2, cortisol, and / or leracolinant on cytokine secretion and gene expression of isolated human NK cells. Addition of leracolinant improved secretion of interferon gamma (IFNγ) compared to NK cells treated with cortisol alone. FIG. 12B. Effect of stimulation with IL-2, cortisol, and / or leracolinant on cytokine secretion and gene expression of isolated human NK cells. Addition of leracolinant improved secretion of tumor necrosis factor (TNFα) compared to NK cells treated with cortisol alone. FIG. 12C. Effect of stimulation with IL-2, cortisol, and / or leracolinant on cytokine secretion and gene expression of isolated human NK cells. Addition of leracolinant improved secretion of granzyme A compared to NK cells treated with cortisol alone.
[0028] [Figure 12D] Figure 12D. Effect of stimulation with IL-2, cortisol, and / or relaxylant on gene expression in isolated human NK cells. Transcription of IFNG (encoding IFNγ) is also increased by relaxylant, in addition to other important regulators of NK activity, including LAG3 and IL2RA (encoding the interleukin 2 (IL2) receptor).
[0029] [Figure 13A] Figure 13A. Glucocorticoids suppress tumor cell killing by human NK cells in vitro. K562 cell killing at various effector:tumor cell ratios under treatment conditions described in the legend. This is counteracted by relacorilant.
[0030] [Figure 13B] FIG 13B. Glucocorticoids suppress tumor cell killing by human NK cells in vitro. At a 5:1 effector:tumor cell ratio, the marked decrease in tumor cell killing in the presence of cortisol is counteracted by relacorilant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] A. Introduction Applicants analyzed the transcription of adrenal cortical carcinoma (ACC) tumor genes. The data was screened to identify tumors with glucocorticoid (GC) excess (e.g., excess cortisol). Applicants identified the gene transcripts in ACC patients and those without ACC. Applicants found that cortisol excess alters the expression of 858 genes in adrenocortical carcinoma (ACC). Specifically, natural killer cell (NK)-mediated cytotoxicity, T H 17 cell differentiation, T cell receptor signaling, T H Genes involved in 1 / 2 differentiation and antigen processing and presentation were downregulated in hypercortisolic ACC patients (GC+; Figure 1). Additional differences are noted in Figure 1 and elsewhere herein. There are.
[0032] Applicants also found that the presence of certain immune cells differed in ACC tumors with and without cortisol excess: naive and memory CD4+ cells, CD8+ cells, CD8+ central memory cells, and natural killer T cells (NKT) were less abundant in GC+ cases (see Figure 2). In contrast, tumor-associated neutrophils (TAN) were more abundant in GC+ ACC patients.
[0033] Patients' clinical responses to antibody checkpoint inhibitors depend on the immune system. Specifically, T cell function and antigen presentation are important for the clinical efficacy of antibody checkpoint inhibitors. Furthermore, immune cell infiltration into tumors is associated with the clinical efficacy of antibody checkpoint inhibitors. Tumors with low T cell numbers or high neutrophil infiltration tend to respond poorly to antibody checkpoint inhibitors.
[0034] Applicants disclose that administering an antibody checkpoint inhibitor in conjunction with administration of an SGRM, which administration of the SGRM is effective to reduce or reverse the effects of excess cortisol in hypercortisolic ACC patients, improves the response of ACC patients to antibody checkpoint inhibitor administration, thereby improving the treatment of hypercortisolic ACC patients. In embodiments, administration of an SGRM in combination with an antibody checkpoint inhibitor is effective to reduce or reverse the effects of excess cortisol in hypercortisolic ACC patients and may be effective in reducing ACC tumor burden in patients.
[0035] Applicant further discloses herein administering an antibody checkpoint inhibitor in conjunction with administration of an SGRM, where administration of the SGRM is effective to restore T cell and NK cell signaling pathways in a patient, including the patient's ACC tumor. Such restoration of T cell and NK cell signaling pathways may improve the patient's response to administration of the antibody checkpoint inhibitor, and thus improve treatment of hypercortisolic ACC patients. In embodiments, administration of an SGRM effective to restore T cell and NK cell signaling pathways in a patient, including the patient's ACC tumor, may be effective to reduce the patient's ACC tumor burden.
[0036] Applicant further discloses herein administering an antibody checkpoint inhibitor in conjunction with administration of an SGRM, where administration of the SGRM is effective to increase infiltration of T cells and NK cells into the patient's ACC tumor. Such increased infiltration of T cells and NK cells may improve the patient's response to administration of the antibody checkpoint inhibitor and improve treatment of hypercortisolic ACC patients. In embodiments, administration of an SGRM effective to increase infiltration of T cells and NK cells into the patient's ACC tumor may be effective to reduce the patient's ACC tumor burden.
[0037] Applicant further discloses herein administering an antibody checkpoint inhibitor in conjunction with administration of an SGRM, where administration of the SGRM is effective to reduce neutrophil infiltration into the patient's ACC tumor. Such reduction in neutrophil infiltration may improve the patient's response to administration of the antibody checkpoint inhibitor, and thus improve the treatment of hypercortisolic ACC patients. In embodiments, administration of an SGRM effective to reduce neutrophil infiltration into the patient's ACC tumor may be effective to reduce the patient's ACC tumor burden.
[0038] B. Definition The term "about" when used in reference to a given value indicates a range that includes ±10% of the given value.
[0039] Information regarding cancer is available, for example, in The Cancer Genome Atlas (TGCA), which can be accessed via the National Cancer Institute's website (www.cancer.gov) at the following page: about-nci / organization / ccg / research / structural-genomics / tcga. The following abbreviations are used herein to refer to various cancers:
[0040] [Table 1]
[0041] As used herein, the terms "tumor" and "cancer" are used interchangeably and both refer to abnormal tissue growth resulting from excessive cell division. Tumors that can invade surrounding tissues and / or metastasize are referred to as "malignant." Tumors that do not metastasize are referred to as "benign."
[0042] As used herein, the terms "adrenal cortical carcinoma" and the acronym "ACC" are used interchangeably to refer to adrenal adenocarcinoma.
[0043] As used herein, the terms "natural killer cells" and their abbreviations, including plural forms thereof, "NK cells," "NKT cells," and the like, are used as known in the art to refer to the cytotoxic lymphocytes of the immune system.
[0044] As used herein, the term "T cells" is used to refer to thymus-derived lymphocytes that play a key role in the immune response, as known in the art.
[0045] As used herein, the term "neutrophil" is used to refer to the most abundant type of white blood cell in mammals, and neutrophils are the most abundant type of granulocyte, as known in the art. Neutrophils are sometimes also referred to as "neutrocytes."
[0046] As used herein, the term "infiltration" is used to refer to the invasion and occupation of one tissue by cells (such as T cells, NK cells, neutrophils, etc.) derived from another tissue.
[0047] As used herein, the term "patient" refers to a human who is receiving, will be receiving, or has received medical treatment for a disease or condition.
[0048] As used herein, the terms "administer," "administering," "administered," or "administration" refer to the administration of a compound or composition (e.g., those described herein) to a subject. Administration to a subject or patient. For example, the compound or composition may be orally administered to the patient.
[0049] As used herein, the terms "administer," "administering," "administered," or "administration" refer to giving a compound or composition (e.g., those described herein) to a subject or patient. Administration may be by oral administration (i.e., the subject receives the compound or composition via the mouth as a pill, capsule, liquid, or other form suitable for administration via the mouth. Oral administration may be buccal (the compound or composition is held in the mouth, e.g., under the tongue, where it is absorbed). Administration may be by injection, i.e., by delivering the compound or composition via a needle, microneedle, pressure syringe, or any means that pierces the skin or forces the compound or composition through the subject's skin. Injection may be intravenous (i.e., into a vein); intraarterial (i.e., into an artery); intraperitoneal (i.e., into the peritoneum); intramuscular (i.e., into a muscle); or other injection route. Routes of administration may also include rectal, intravaginal, transdermal, via the lungs (e.g., by inhalation), subcutaneous (e.g., by absorption into the skin from an implant containing the compound or composition), or by other routes.
[0050] As used herein, the term "adrenocorticotropic hormone" (ACTH) refers to a peptide hormone produced and secreted by the anterior pituitary gland that stimulates the adrenal cortex to secrete glucocorticoid hormones that help cells synthesize glucose, catabolize proteins, mobilize free fatty acids, and inhibit inflammation in allergic reactions. One such glucocorticoid hormone is cortisol, which regulates carbohydrate, fat, and protein metabolism. In healthy mammals, ACTH secretion is tightly regulated. ACTH secretion is positively regulated by corticotropin-releasing hormone (CRH) released by the hypothalamus. ACTH secretion is negatively regulated by cortisol and other glucocorticoids.
[0051] In the context of ACTH, cortisol, or other analytes, the term "measuring the level" refers to determining, detecting, or quantifying the amount, level, or concentration of cortisol, ACTH, or other analyte in a sample obtained, for example, from a subject. The sample can be, for example, a blood sample, a saliva sample, a urine sample, or other sample obtained from a patient. The level can be measured from a fraction of the sample. For example, the level (e.g., ACTH or cortisol) can be measured in the plasma fraction of a blood sample; in the serum fraction of a blood sample; in embodiments, in whole blood; in saliva; in urine; or other. It may also be measured in body fluids.
[0052] The term "cortisol" refers to the natural glucocorticoid hormone (also known as hydrocortisone) produced by the zona fasciculata of the adrenal gland. Cortisol has the following structure:
[0053] [ka]
[0054] The term "total cortisol" refers to cortisol bound to cortisol binding globulin (CBG or transcortin) and free cortisol (cortisol not bound to CBG). The term "free cortisol" refers to cortisol not bound to cortisol binding globulin (CBG or transcortin). As used herein, the term "cortisol" refers to total cortisol, free cortisol, and / or cortisol bound to CBG.
[0055] Cortisol levels can be measured in blood (e.g., serum or plasma), urine, saliva, and other body fluids. Urinary free cortisol (UFC, a measure of urinary cortisol excreted over a 24-hour period) is a common method of measuring cortisol levels and requires a full day's worth of samples, thereby covering cortisol fluctuations over the course of a day. Plasma cortisol (a measure of cortisol levels at the time the blood sample is taken) is often used in dexamethasone suppression tests, which test a patient's response to a surge in glucocorticoid levels. Cortisol levels can also be measured in serum samples according to methods known in the art. Salivary cortisol may also be measured. Numerical values of cortisol vary between assays; i.e., blood cortisol levels (e.g., serum or plasma levels) sample cortisol at the time the blood sample is taken and are numerically different from salivary cortisol levels (which sample cortisol at the time the saliva sample is taken) and are numerically different from urinary free cortisol levels (which represent cortisol levels over a 24 hour period).
[0056] Cortisol levels can be measured in a sample (e.g., serum, plasma, saliva, urine, or any other biological fluid) using a variety of methods, including, but not limited to, immunoassays, such as competitive immunoassays, radioimmunoassays (MA), immunofluorescence quantitative enzyme assays, and ELISA; competitive protein binding assays; liquid chromatography (e.g., HPLC); and mass spectrometry, such as high performance liquid chromatography / triple quadrupole mass spectrometry (LC-MS / MS). In a preferred embodiment, cortisol levels are measured using LC-MS / MS, such as by Quest Diagnostics (Secaucus, NJ 07094).
[0057] The term "normal value" refers to the average value of an analyte determined by measuring samples obtained from multiple healthy subjects. For comparison, the same type of measurement (e.g., plasma or serum; saliva; or urine) should be used as the reference.
[0058] The term "normal cortisol level" refers to the average cortisol level determined by measuring samples (e.g., serum samples) obtained from multiple healthy subjects. For example, Putignano et al. (European Journal of Endocrinology, Vol. 145: pp. 165-171 (2001)) reported that normal plasma cortisol levels in healthy women were Cortisol was approximately 420 nanomoles per liter (nmol / l) at 8:00 AM (morning); approximately 250 nmol / l at 5:00 PM (evening); and approximately 90 nmol / l at 12:00 PM (midnight). Salivary cortisol measurements obtained from these women were approximately 14 nmol / l at 8:00 AM (morning); approximately 7 nmol / l at 5:00 PM (evening); and approximately 5 nmol / l at 12:00 PM (midnight). Urinary free cortisol levels measured in these healthy women were approximately 130 nmol per 24 hours (nmol / 24h). Cortisol levels are suppressed by the dexamethasone suppression test (DST), as shown by plasma cortisol levels of approximately 24 nmol / l after the DST and salivary cortisol levels of approximately 4 nmol / l after the DST.
[0059] Applicants have discovered that measuring cortisol levels in patients with ACC tumors allows for the identification of patients who would benefit from combination treatment with an SGRM and an antibody checkpoint inhibitor by determining whether the patient has cortisol excess.
[0060] As used herein, the term "cortisol excess" refers to a cortisol level greater than about 1.5 times, or greater than about 2 times, the cortisol level measured in a healthy subject, regardless of the method of measurement, where the cortisol level in the healthy subject is measured by the same method as the patient's cortisol is measured. For example, using the morning plasma cortisol levels of Putignano et al., a patient would be determined to have cortisol excess if he or she has a morning plasma cortisol level of about 630 nmol / l or greater, or about 840 nmol / l or greater. Using the morning salivary cortisol levels of Putignano et al., a patient would be determined to have cortisol excess if he or she has a morning salivary cortisol level of about 21 nmol / l or greater, or about 28 nmol / l or greater. Using the 24-hour urinary free cortisol values of Putignano et al., a patient would be considered to have cortisol excess if they had a 24-hour urinary cortisol value of about 195 nmol / 24 hours or greater, or about 260 nmol / 24 hours or greater.
[0061] In some embodiments, multiple criteria may be used to identify patients with cortisol excess. For example, two or more, or all or any of the following criteria may be used to determine whether a patient exhibits cortisol excess: 1. Urinary free cortisol (UFC) exceeds the upper limit of normal (ULN) 2. Late-night salivary cortisol (LNSC) levels above the ULN for two nights 3. Cortisol levels exceeding 1.8μg / dL in the dexamethasone suppression test (DST) 4. Adrenocorticotropic hormone (ACTH) levels less than 10 picograms per milliliter (pg / mL)
[0062] "Standard control" as used herein refers to a sample containing a predetermined amount of an analyte (such as ACTH or cortisol) suitable for use in the present invention to provide a comparison standard that provides an indication of the relative amount of the analyte (e.g., ACTH or cortisol) present in a test sample. A sample serving as a standard control provides an average content of an analyte, such as ACTH or cortisol, representative of a defined sample type (e.g., plasma, serum, saliva, or urine) taken at a defined time (e.g., 8:00 a.m.) from an average individual who does not have or is not at high risk for subsequent development of hypokalemia or any related disorder or complication, and who has undergone the same GRM procedure. As used herein, a "blood sample" can be a whole blood sample, a serum sample, a plasma sample, or a blood cell sample, as appropriate, for measuring the analyte level by methods known in the art according to conventional use. Similarly, a "blood level" of a particular analyte can be the level of the analyte in whole blood, serum, plasma, or blood cells. For example, the blood levels of potassium, ACTH, or cortisol can be the level of the respective analyte in a serum or plasma sample taken from the subject under test.
[0063] The term "average," when used in the context of describing individuals (particularly human subjects) who do not have and are not at high risk for developing hypokalemia or any associated disease or disorder prior to undergoing GRM treatment, refers to a particular characteristic, such as the level or content of an analyte (such as ACTH or cortisol) present in a sample taken from individuals not undergoing GRM treatment, that represents the average content or mean level of that analyte present in a randomly selected population of individual subjects who have not been diagnosed with and are not susceptible to hypokalemia or any associated disease or condition, and therefore may serve as the "average normal value" or "standard control value" of the particular analyte prior to GRM treatment. This selection should include a sufficient number of individuals (e.g., at least 200 or 500) such that the average value (i.e., level or content) of the analyte of interest (e.g., ACTH or cortisol) assessed among individuals reflects with a reasonable degree of accuracy the corresponding level or content of that analyte present in a population of non-hypokalemic individuals with no known risk of disorder or associated disease upon undergoing GRM treatment. In some cases, the sample population will usually be of the same sex, of similar age (e.g., within 5 or 10 years of each other), and of similar ethnic and medical backgrounds. Depending on the analyte, it may be necessary to ascertain the mean or standard control value from samples taken from these individuals at approximately the same time (e.g., 6:00 AM, 8:00 AM, 12:00 PM (12 PM), 4:00 PM, or 6:00 PM). The mean or standard control value for a particular analyte may also vary depending on the specific assay or assay format (including the specific reagents) utilized to quantitatively measure the analyte, and may be made available by experimental methodology or assay manufacturer information.
[0064] The term "glucocorticosteroid" ("GC") or "glucocorticoid" refers to a steroid hormone that binds to the glucocorticoid receptor. Glucocorticosteroids are typically characterized as having 21 carbon atoms, an α,β-unsaturated ketone in the A ring, and an α-ketol group attached to the D ring. Glucocorticosteroids vary in the degree of oxygenation or hydroxylation at C-11, C-17, and C-19. See Rawn, "Biosynthesis and Transport of Membrane Lipids and Formation of Cholesterol Derivatives," Biochemistry, Daisy et al. (eds.), 1989, p567. Cortisol is a glucocorticosteroid.
[0065] The mineralocorticoid receptor (MR), also known as the type I glucocorticoid receptor (GR I), is activated by aldosterone in humans.
[0066] As used herein, the term "glucocorticoid receptor" ("GR") refers to type II GR, a family of intracellular receptors that specifically bind cortisol and / or cortisol analogs, such as dexamethasone (see, e.g., Turner & Muller, J. Mol. Endocrinol. October 1, 2005 35 283-292). The glucocorticoid receptor is also referred to as the cortisol receptor. The term also includes isoforms of GR, recombinant GR, and mutant GR.
[0067] The term "glucocorticoid receptor modulator" (GRM) refers to any compound that modulates GC binding to GR or modulates any biological response associated with GR binding to agonist. For example, GRM acting as agonist, such as dexamethasone, increases the activity of tyrosine aminotransferase (TAT) in HepG2 cells (human liver hepatocellular carcinoma cell line; ECACC, UK). GRM acting as antagonist, such as mifepristone, decreases the activity of tyrosine aminotransferase (TAT) in HepG2 cells. TAT activity can be measured as outlined in the article by A. Ali et al., J.Med.Chem., 2004, 47, 2441-2452.
[0068] As used herein, the term "selective glucocorticoid receptor modulator" (SGRM) refers to any composition or compound that modulates GC binding to GR or modulates any biological response associated with GR binding to an agonist. By "selective," the drug preferentially binds to GR rather than other nuclear receptors such as the progesterone receptor (PR), mineralocorticoid receptor (MR), or androgen receptor (AR). Such selective glucocorticoid receptor modulators have a 10-fold greater affinity (K) for MR, AR, or PR, both MR and PR, both MR and AR, both AR and PR, or MR, AR, and PR. d In a more preferred embodiment, the selective glucocorticoid receptor modulator binds to GR with an affinity that is 100-fold greater (K) than its affinity for MR, AR, or PR; both MR and PR; both MR and AR; both AR and PR; or MR, AR, and PR. d In another embodiment, the selective glucocorticoid receptor modulator binds to GR with an affinity that is 1000 times greater (K) than its affinity for MR, AR, or PR; both MR and PR; both MR and AR; both AR and PR; or MR, AR, and PR. dRelacorilant binds to GR with an affinity (1 / 1000th of the value of the receptor).
[0069] "Glucocorticoid receptor antagonist" (GRA) refers to any compound that inhibits GC binding to GR or inhibits any biological response associated with the binding of GR to an agonist. Thus, GR antagonists can be identified by measuring the ability of a compound to inhibit the effect of dexamethasone. TAT activity can be measured as outlined in the article by A. Ali et al., J. Med. Chem., 2004, 47, 2441-2452. Antagonists have an IC of less than 10 micromolar. 50 (half-maximal inhibitory concentration). See Example 1 of U.S. Patent No. 8,859,774, the entire contents of which are incorporated herein by reference in their entirety.
[0070] As used herein, the term "selective glucocorticoid receptor antagonist" (SGRA) refers to any composition or compound that inhibits GC binding to GR or modulates any biological response associated with GR binding to an agonist (inhibition being determined with respect to said response in the absence of said compound). By "selective" it is meant that the drug preferentially binds to GR rather than other nuclear receptors such as the progesterone receptor (PR), mineralocorticoid receptor (MR) or androgen receptor (AR). The selective glucocorticoid receptor antagonist has a 10-fold greater affinity (K) for MR, AR, or PR; both MR and PR; both MR and AR; both AR and PR; or MR, AR, and PR. d In a more preferred embodiment, the selective glucocorticoid receptor antagonist binds to GR with an affinity that is 100-fold greater (K) than its affinity for MR, AR, or PR; both MR and PR; both MR and AR; both AR and PR; or MR, AR, and PR. dIn another embodiment, the selective glucocorticoid receptor antagonist binds to GR with an affinity that is 1000 times greater (K) than its affinity for MR, AR, or PR; both MR and PR; both MR and AR; both AR and PR; or MR, AR, and PR. d It binds to GR with an affinity that is 1 / 1000th of the value of that of the GR. Relacorilant (CORT125134) is an SGRA.
[0071] As used herein, the phrase "not suitable for treatment with a glucocorticoid receptor modulator" refers to a patient who is not suffering from any condition recognized by the medical community as being effectively treatable with a glucocorticoid receptor antagonist, except for fatty liver. Conditions known in the art and recognized by the medical community as being effectively treatable with a glucocorticoid receptor antagonist include psychosis associated with interferon alpha therapy, psychotic major depression, dementia, stress disorders, autoimmune diseases, neurological damage, and Cushing's syndrome.
[0072] The term "immune response" refers to the action of lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules produced by such cells or the liver, including antibodies, cytokines, and complement, that result in the selective damage, selective destruction, or elimination from the body of invading pathogens, pathogen-infected cells or tissues, cancerous cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.
[0073] As used herein, the term "checkpoint inhibitor-sensitive cancer" refers to a cancer that is responsive to a checkpoint inhibitor. Administration of one or more checkpoint inhibitors to a patient with such a tumor may result in a reduction in ACC tumor burden, restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and decreased infiltration of neutrophils into ACC tumors, or other desired beneficial clinical outcomes associated with cancer improvement in the patient.
[0074] As used herein, the term "effective amount" or "therapeutic amount" refers to an amount of drug effective to treat, eliminate, or alleviate at least one symptom of the disease being treated. In some cases, "therapeutically effective amount" or "effective amount" may refer to an amount of a functional agent or pharmaceutical composition useful for exhibiting a detectable therapeutic or inhibitory effect. This effect can be detected by any assay method known in the art. An effective amount can be an amount effective to induce an anti-tumor response. An effective amount can be an amount effective to induce a therapeutically beneficial response (e.g., an anti-tumor immune response, a humoral immune response, and / or a cellular immune response) in a recipient subject, for example, to inhibit the growth or kill a target cell. For purposes of this disclosure, an effective amount of an SGRM or antibody checkpoint inhibitor (and, optionally, a chemotherapeutic agent) is an amount that will cause a reduction in ACC tumor burden, restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and decreased infiltration of neutrophils into ACC tumors, or other desired beneficial clinical outcome associated with cancer amelioration in a patient.
[0075] As used herein, the phrase "an effective amount to enhance" refers to an amount of a drug that is effective to enhance the activity of another therapeutic agent in treating, eliminating, or alleviating at least one symptom of the disease being treated. For example, an effective amount of an SGRM administered in combination with an antibody checkpoint inhibitor is an amount of the SGRM that enhances the therapeutic response to the antibody checkpoint inhibitor. An agent used to enhance the activity of another agent may or may not be effective in treating, eliminating, or alleviating a disease symptom by itself. In some cases, the enhancer has no effect, and the synergistic effect can be shown by an increase in symptom relief resulting from treatment with the combination of the two agents compared to treatment with the therapeutic agent alone. In some cases, the enhancer is effective in treating a symptom by itself, and the enhancing effect can be shown by a synergistic effect between the enhancer and the therapeutic agent. For purposes of this disclosure, the SGRM acts as an enhancer that enhances the activity of a checkpoint inhibitor in treating cancer, regardless of whether it is effective in treating the cancer when administered alone. In some embodiments, an enhancing effect of 10% to 1000% can be achieved. In some embodiments, the SGRM is administered in an amount that sensitizes the tumor to a checkpoint inhibitor, i.e., an amount that shows in the patient a reduction in ACC tumor burden, restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and decreased infiltration of neutrophils into ACC tumors, or other relevant clinical benefit that is not seen when the tumor is treated with an antibody checkpoint inhibitor in the absence of the SGRM.
[0076] As used herein, the term "combination therapy" refers to the administration of at least two pharmaceutical agents to a subject to treat a disease. The two agents may be administered simultaneously or sequentially in any order during all or part of the treatment period. The two agents may be administered according to the same dosing schedule or according to different dosing schedules. In some cases, one agent is administered according to a scheduled schedule and the other agent is administered intermittently. In some cases, both agents are administered intermittently. In some embodiments, one agent, e.g., an SGRM, is administered daily and the other agent, e.g., an antibody checkpoint inhibitor, is administered every 2, 3, or 4 days, or every week or every other week.
[0077] As used herein, the term "co-administered" refers to administration of two compositions at the same time or within a short period of time of each other, for example, within about 0.5 hours, within about 1 hour, within about 2 hours, within about 4 hours, within about 6 hours, within about 8 hours, within about 10 hours, within about 12 hours, within about 16 hours, within about 20 hours, or within about 24 hours of each other.
[0078] As used herein, the term "checkpoint protein" refers to a protein present on the surface of certain types of cells, such as T cells and certain tumor cells, that can induce checkpoint signaling pathways leading to suppression of immune responses. Commonly known checkpoint proteins include CTLA4, PD-1, PD-L1, LAG3, B7-H3, B7-H4, TIM3, CD160, CD244, VISTA, TIGIT, and BTLA (Pardoll, 2012, Nature Reviews Cancer, vol. 12: pp252-264; Baksh, 2015, Semin Oncol., June 2015; vol. 42(3): pp363-77). Among these, CTLA4, PD-1, and PD-L1 are the most well-studied, and treatments targeting these proteins are more advanced in the clinical stage than treatments targeting other checkpoint proteins.
[0079] As used herein, the term "PD-1" refers to programmed cell death protein 1 (also known as CD279), a cell surface membrane protein of the immunoglobulin superfamily. PD-1 is expressed by B cells, T cells, and NK cells. The primary role of PD-1 is to limit T cell activity in peripheral tissues during inflammation in response to infection and to limit autoimmunity. PD-1 expression is induced on activated T cells, and binding of PD-1 to one of its endogenous ligands acts to inhibit T cell activation by inhibiting stimulatory kinases. PD-1 also acts to inhibit the TCR "stop signal." PD-1 is highly expressed on Treg cells (regulatory T cells) and can increase proliferation of Treg cells in the presence of ligand (Pardoll, 2012, Nature Reviews Cancer, vol. 12:pp252-264).
[0080] As used herein, the term "PD-L1" refers to the ligand of PD-1, programmed cell death 1 ligand 1 (also known as CD274 and B7-H1). PD-L1 is present on activated T cells, B cells, myeloid cells, macrophages, and tumor cells. PD-1 has two endogenous ligands, PD-L1 and PD-L2, but antitumor therapy has focused on anti-PD-L1. The complex of PD-1 and PD-L1 inhibits the proliferation of CD8+ T cells and reduces the immune response (Topalian et al., 2012, N. Engl J. Med., 366:2443-54; Brahmer et al., 2012, N. Engl J. Med., 366:2455-65).
[0081] As used herein, the term "CTLA4" refers to cytotoxic T-lymphocyte antigen 4 (also known as CD152), a member of the immunoglobulin superfamily that is expressed exclusively on T cells. CTLA4 acts to inhibit T-cell activation and has been reported to suppress the activity of helper T cells and enhance the immunosuppressive activity of regulatory T cells. Although the exact mechanism of action of CTL4-A is still under investigation, it has been suggested that CTL4-A inhibits T-cell activation by competing with and outcompeting CD28 for binding to CD80 and CD86 on antigen-presenting cells, and also actively delivers inhibitory signals to T cells (Pardoll, 2012, Nature Reviews Cancer, vol. 12:pp252-264).
[0082] As used herein, the term "checkpoint inhibitor" refers to any molecule, including antibodies and small molecules, that blocks immune suppressive pathways induced by one or more checkpoint proteins. Therapeutics utilizing checkpoint inhibitors to treat disorders such as cancer may be referred to as immune system checkpoint inhibitor therapy, and the acronym "ICI" refers to immune system checkpoint inhibitors. In some embodiments, ICI therapy utilizes an antibody checkpoint inhibitor and includes administering an antibody checkpoint inhibitor to a patient in need of such therapy, and the therapy may be a combination therapy that includes combining a GRM, SGRM, GRA, or SGRA with an antibody checkpoint inhibitor. In some embodiments, ICI therapy utilizes a small molecule checkpoint inhibitor and includes administering a small molecule checkpoint inhibitor to a patient in need of such therapy, and the therapy may be a combination therapy that includes combining a GRM, SGRM, GRA, or SGRA with a small molecule checkpoint inhibitor.
[0083] As used herein, the term "antibody checkpoint inhibitor" refers to an antibody that blocks an immunosuppressive pathway induced by one or more checkpoint proteins. Therapeutic methods that utilize checkpoint inhibitors to treat disorders such as cancer may be referred to as, for example, antibody checkpoint inhibitor therapy. In some embodiments, antibody checkpoint inhibitor therapy includes administering an antibody checkpoint inhibitor to a patient in need of such therapy, and the therapy may be a combination therapy that includes a GRM, SGRM, GRA, or SGRA in combination with an antibody checkpoint inhibitor.
[0084] As used herein, the term "antibody effective against checkpoint protein" refers to an antibody that can bind to a checkpoint protein and antagonize the function of the checkpoint protein in suppressing immune response. For example, an antibody against PD-1 refers to an antibody that can bind to PD-1 and block the inhibitory function of PD-1 on immune response, such as by blocking the interaction between PD-1 and PD-L1. In some cases, there may be an antibody against two types of checkpoint proteins, i.e., an antibody that has the ability to bind to two types of checkpoint proteins and inhibit their functions. An "antibody effective against a checkpoint protein" is an "antibody checkpoint inhibitor".
[0085] As used herein, the term "antibody" includes not only full-length antibodies, but also "antigen-binding portions" of antibodies. The term "antigen-binding portion" as used herein refers to one or more antibody fragments that retain the ability to specifically bind to an antigen (e.g., PD-1). Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include (i) a Fab fragment, which is a monovalent fragment consisting of the VL domain, the VH domain, the CL domain, and the CH1 domain; (ii) an F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments cross-linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH domain and the CH1 domain; (iv) an Fv fragment consisting of the VL domain and the VH domain of a single arm of an antibody; (v) a dAb fragment consisting of the VH domain (Ward et al., (1989), Nature, vol. 341: pp. 544-546); and (vi) an isolated complementarity determining region (CDR). Furthermore, the two domains of the Fv fragment, VL and VH, are encoded by separate genes, but can be linked using recombinant techniques by a synthetic linker that allows the VL and VH regions to pair into a single protein chain forming a monovalent molecule (known as single chain Fv (scFv); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; and Osbourn et al., 1998, Nature Biotechnology 16:778). Such single chain antibodies are also intended to be encompassed by the term "antigen-binding portion" of an antibody. Any VH and VL sequence of a particular scFv can be linked to cDNA or genomic sequences of human immunoglobulin constant regions to generate expression vectors encoding complete IgG molecules or other isotypes. The VH and VI can also be used to generate immunoglobulin fragments such as Fab or Fv using either protein chemistry or recombinant DNA techniques. Other forms of single chain antibodies, such as diabodies, are also contemplated.A diabody is a bivalent, bispecific antibody in which a VH domain and a VL domain are expressed on a single polypeptide chain, but because the linker used is too short to allow pairing between the two domains on the same chain, each domain pairs with a complementary domain on another chain, forming two antigen-binding sites (see, for example, Holliger, P. et al. (1993) Proc. Natl. Acad. Sci. USA, 90:6444-6448; Poljak, RJ et al. (1994) Structure, 2:1121-1123).
[0086] The antibody may be a polyclonal or monoclonal antibody; a heterologous, allologous, or syngeneic antibody; or modified versions thereof, such as humanized, chimeric, etc. The antibody of the present invention binds specifically or highly specifically to one or more checkpoint proteins. The term "monoclonal antibody" refers to a population of antibody molecules that contain only one antigen-binding site capable of immunoreacting with a particular epitope of an antigen, whereas the terms "polyclonal antibody" and "polyclonal antibody composition" refer to a population of antibody molecules that contain multiple antigen-binding sites capable of interacting with a particular antigen. A monoclonal antibody composition typically exhibits a single binding affinity for a particular antigen with which it immunoreacts.
[0087] As used herein, the term "composition" is intended to encompass products that include specific components, such as the above compounds, their tautomeric forms, their derivatives, their analogs, their stereoisomers, their polymorphs, their deuterated species, their pharma- ceutically acceptable salts, esters, ethers, metabolites, mixtures of isomers, their pharma- ceutical acceptable solvates, and pharma- ceutical acceptable compositions, in specific amounts, as well as any products that are obtained directly or indirectly from the combination of the specific components in specific amounts. Such terms relating to pharmaceutical compositions are intended to encompass products that include active ingredient(s) and inactive ingredient(s) that constitute the carrier, as well as any products that result, directly or indirectly, in the combination, conjugation, or aggregation of any two or more of the components, or that result from the dissociation of one or more of the components, or from any other type of reaction or interaction of one or more of the components. Thus, the pharmaceutical compositions of the present invention are intended to encompass any compositions made by combining the compounds of the present invention and their pharma- ceutical acceptable carriers.
[0088] In some embodiments, the term "consisting essentially of" refers to a composition in a formulation in which the active ingredient is the only active ingredient indicated, but other compounds may be included for stabilization, preservation, etc. of the formulation, but are not directly involved in the therapeutic effect of the indicated active ingredient. In some embodiments, the term "consisting essentially of" can refer to a composition containing the active ingredient and a component that facilitates the release of the active ingredient. For example, the composition may contain one or more components that provide a sustained release of the active ingredient to a subject over time. In some embodiments, the term "consisting of" refers to a composition containing the active ingredient and a pharma- ceutically acceptable carrier or excipient.
[0089] As used herein, the term "compound" is used to refer to a molecular component of a unique, identifiable chemical structure. A molecular component ("compound") may exist in the form of a free species, not associated with other molecules. A compound may also exist as part of a larger aggregate, associated with other molecules but retaining its chemical identity. A solvate is an example of the above combination form, in which a molecular component ("compound") with a defined chemical structure is associated with a solvent molecule. A hydrate is a solvate in which the associated solvent is water. A "compound" refers to the molecular component itself (whose structure is shown), whether it exists in free form or in combined form.
[0090] Substituents, when specified by these conventional chemical formulas written from left to right, equally encompass the chemically identical substituents that would result from writing the structures from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0091] Substituents, when specified by these conventional chemical formulas written from left to right, equally encompass the chemically identical substituents that would result from writing the structures from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0092] "Alkyl" refers to a straight or branched chain saturated aliphatic radical having the number of carbon atoms indicated. 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 1-7 , C 1-8 , C 1-9 , C 1-10 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 , and C 5-6 For example, C 1-6Alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, and hexyl.
[0093] "Alkoxy" refers to an alkyl group having an oxygen atom connecting the alkyl group to the point of attachment: alkyl-O-. With respect to said alkyl group, an alkoxy group is one having a C 1-6 Alkoxy groups can have any suitable number of carbon atoms, such as, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like.
[0094] "Halogen" refers to fluorine, chlorine, bromine and iodine.
[0095] "Haloalkyl" refers to an alkyl as defined above in which some or all of the hydrogen atoms are replaced by halogen atoms. With respect to the alkyl group, the haloalkyl group includes C 1 -C 2 -C 3 -C 4 -C 5 -C 6 -C 7 -C 8 -C 9 -C 10 -C 11 -C 12 -C 13 -C 14 -C 15 -C 16 -C 17 -C 18 -C 19 -C 20 -C 21 -C 22 -C 23 -C 24 -C 25 -C 36 -C 17 -C 26 -C 37 -C 18 -C 27 -C 38 -C 39 -C 40 -C 50 -C 28 -C 39 -C 41 -C 51 -C 29 -C 39 -C 42 -C 52 -C 39 -C 53 1-6 The group may have any suitable number of carbon atoms, such as
[0096] The term "perfluoro" can be used to define a compound or radical in which all hydrogens have been replaced by fluorines. For example, perfluoromethane includes 1,1,1-trifluoromethyl.
[0097] "Haloalkoxy" refers to an alkoxy group in which some or all of the hydrogen atoms are replaced by halogen atoms. With respect to the alkyl groups described above, the haloalkoxy group is 1-6The alkoxy group may have any suitable number of carbon atoms, such as 1, 2, 3, or more than 1. The alkoxy group may be substituted by one, two, three, or more halogens. When all hydrogens are replaced by halogens, such as fluorine, the compound is persubstituted, such as perfluorinated. Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, and perfluoroethoxy.
[0098] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic, fused bicyclic, or bridged polycyclic ring assembly containing 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl is any of the groups represented by C 3-6 , C 4-6 , C 5-6 , C 3-8 , C 4-8 , C 5-8 , C 6-8 , C 3-9 , C 3-10 , C 3-11 , and C 3-12 Cycloalkyl groups may have any number of carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene, and adamantane. Cycloalkyl groups may be partially unsaturated, with one or more double or triple bonds in the ring. Representative cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4-, and 1,5-isomers), norbornene, and norbornadiene. Cycloalkyl groups may be saturated monocyclic C 3-8 When cycloalkyl, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. 3-6When it is cycloalkyl, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0099] "Heterocycloalkyl" refers to a saturated ring system having 3-12 ring members and 1-4 heteroatoms of N, O, and S. Additional heteroatoms may also be useful, including but not limited to B, Al, Si, and P. The heteroatoms may also be oxidized, such as, but not limited to, -S(O)- and -S(O)2-. Heterocycloalkyl groups may contain any number of ring atoms, such as 3-6, 4-6, 5-6, 3-8, 4-8, 5-8, 6-8, 3-9, 3-10, 3-11, or 3-12 ring members. The heterocycloalkyl groups may contain any suitable number of heteroatoms, such as 1, 2, 3, or 4, or 1-2, 1-3, 1-4, 2-3, 2-4, or 3-4. The heterocycloalkyl groups may include groups such as aziridine, azetidine, pyrrolidine, piperazine, azepane, azocane, quinuclidine, pyrazoline, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxane (tetrahydropyran), oxepane, thiirane, thietane, thiolane (tetrahydrothiophene), thiane (tetrahydrothiopyran), oxazolidine, isoxazine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane, or dithiane. The heterocycloalkyl groups may also be fused with aromatic or non-aromatic ring systems to form members including, but not limited to, indoline.
[0100] When the heterocycloalkyl contains 3 to 8 ring members and 1 to 3 heteroatoms, representative members include, but are not limited to, pyrrolidine, piperazine, tetrahydrofuran, oxane, tetrahydrothiophene, thiane, pyrazoline, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane, and dithiane. The heterocycloalkyl may form a ring having 5 to 6 ring members and 1 to 2 heteroatoms, representative members include, but are not limited to, pyrrolidine, piperazine, tetrahydrofuran, tetrahydrothiophene, pyrazoline, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, and morpholine.
[0101] "Aryl" refers to an aromatic ring system having any suitable number of ring atoms and any suitable number of rings. Aryl groups can contain any suitable number of ring atoms, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 ring atoms, and 6-10, 6-12, or 6-14 ring members. Aryl groups can be monocyclic, fused to form bicyclic or tricyclic groups, or linked by bonds to form biaryl groups. Representative aryl groups include phenyl, naphthyl, and biphenyl. Other aryl groups include benzyl, which has a methylene linking group. Some aryl groups have 6-12 ring members, such as phenyl, naphthyl, or biphenyl. Other aryl groups have 6-10 ring members, such as phenyl or naphthyl. Some other aryl groups have 6 ring members, such as phenyl. Aryl groups can be substituted or unsubstituted.
[0102] "Heteroaryl" refers to a monocyclic, fused bicyclic, or tricyclic aromatic ring assembly containing 5-16 ring atoms, of which 1-5 are heteroatoms such as N, O, or S. Additional heteroatoms may also be useful, including but not limited to B, Al, Si, and P. The heteroatoms may also be oxidized, such as, but not limited to, N-oxide, -S(O)-, and -S(O)2-. Heteroaryl groups may contain any number of ring atoms, such as 3-6, 4-6, 5-6, 3-8, 4-8, 5-8, 6-8, 3-9, 3-10, 3-11, or 3-12 ring members. The heteroaryl groups may contain any suitable number of heteroatoms, such as 1, 2, 3, 4, or 5; or 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, or 3-5. Heteroaryl groups can have 5-8 ring members and 1-4 heteroatoms, or 5-8 ring members and 1-3 heteroatoms, or 5-6 ring members and 1-4 heteroatoms, or 5-6 ring members and 1-3 heteroatoms. The heteroaryl groups can include groups such as pyrrole, pyridine, imidazole, pyrazole, triazole, tetrazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4-, and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. The heteroaryl groups can also be fused with aromatic ring systems such as phenyl rings to form members, including but not limited to, benzopyrroles such as indole and isoindole, benzopyridines such as quinoline and isoquinoline, benzopyrazine (quinoxaline), benzopyrimidine (quinazoline), benzopyridazines such as phthalazine and cinnoline, benzothiophenes, and benzofurans. Other heteroaryl groups contain heteroaryl rings linked by bonds, such as bipyridine.Heteroaryl groups can be substituted or unsubstituted.
[0103] Said heteroaryl group can be linked through any position of its ring.For example, pyrrole includes 1-, 2- and 3-pyrrole;pyridine includes 2-, 3- and 4-pyridine;imidazole includes 1-, 2-, 4- and 5-imidazole;pyrazole includes 1-, 3-, 4- and 5-pyrazole;triazole includes 1-, 4- and 5-triazole;tetrazole includes 1- and 5-tetrazole;pyrimidine includes 2-, 4-, 5- and 6-pyrimidine;pyridazine includes 3- and 4-pyridazine;1,2,3-triazine includes 4- and 5-triazine;1,2,4-triazine includes 3-, 5- and 6-triazine;1,3,5-triazine includes 2-triazine;thiophene includes 2- and 3-thiophene;furan includes 2- and 3-furan; thiazoles include 2-, 4- and 5-thiazoles; isothiazoles include 3-, 4- and 5-isothiazoles; oxazoles include 2-, 4- and 5-oxazoles; isoxazoles include 3-, 4- and 5-isoxazoles; indoles include 1-, 2- and 3-indoles; isoindoles include 1- and 2-isoindole; quinolines include 2-, 3- and 4-quinolines; isoquinolines include 1-, 3- and 4-isoquinolines; quinazolines include 2- and 4-quinoazolines; cinnolines include 3- and 4-cinnolines; benzothiophenes include 2- and 3-benzothiophenes; and benzofurans include 2- and 3-benzofurans.
[0104] Some heteroaryl groups include those having 5 to 10 ring members and 1 to 3 ring atoms containing N, O, or S, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4-, and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, and benzofuran. Other heteroaryl groups include those having 5 to 8 ring members and 1 to 3 heteroatoms, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. Some other heteroaryl groups include those having 9 to 12 ring members and 1 to 3 heteroatoms, such as indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, benzofuran, and bipyridine. Still other heteroaryl groups include those having 5-6 ring members and 1-2 ring heteroatoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, pyrazine, pyrimidine, pyridazine, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
[0105] Some heteroaryl groups contain 5-10 ring members and only nitrogen heteroatoms, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, and cinnoline. Other heteroaryl groups contain 5-10 ring members and only oxygen heteroatoms, such as furan and benzofuran. Some other heteroaryl groups contain 5-10 ring members and only sulfur heteroatoms, such as thiophene and benzothiophene. Still other heteroaryl groups contain 5 to 10 ring members and at least two heteroatoms and include, for example, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiazole, isothiazole, oxazole, isoxazole, quinoxaline, quinazoline, phthalazine, and cinnoline.
[0106] "Heteroatom" refers to O, S, or N.
[0107] "Salt" refers to the acid or base salt of the compound used in the method of the present invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, etc.) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, etc.) salts, and quaternary ammonium (methyl iodide, ethyl iodide, etc.) salts. It is understood that said pharmaceutically acceptable salts are non-toxic. Further information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
[0108] "Isomers" refer to compounds that have the same chemical formula but are structurally distinguishable.
[0109] "Tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one form to the other.
[0110] The description of the compounds of the present invention is limited by the principles of chemical bonding known to those skilled in the art. Thus, when groups may be substituted with one or more of a number of substituents, such substitutions are selected to be compatible with the principles of chemical bonding and to produce compounds that are not inherently unstable and / or that would be known to those skilled in the art to be susceptible to instability under ambient conditions, such as aqueous, neutral, or physiological conditions.
[0111] Non-steroidal compounds include SGRMs with condensed azadecalin skeleton, SGRMs with heteroaryl ketone condensed azadecalin skeleton, and SGRMs with octahydro condensed azadecalin skeleton. Glucocorticoid receptor modulators with condensed azadecalin skeleton include those described in U.S. Patent No. 7,928,237 and U.S. Patent No. 8,461,172. Glucocorticoid receptor modulators with heteroaryl ketone condensed azadecalin skeleton include those described in U.S. Patent No. 8,859,774. Glucocorticoid receptor modulators with octahydro condensed azadecalin skeleton include those described in U.S. Patent No. 10,047,082.
[0112] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to Substances that aid in the administration and absorption of active agents to and by a subject may be included in the compositions of the present invention without causing significant adverse toxic effects to the patient. As used herein, these terms are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, antioxidants, isotonic and absorption retarding agents, etc. that are compatible with drug administration. Non-limiting examples of pharmaceutically acceptable additives include water, NaCl, saline, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, encapsulating agents, plasticizers, lubricants, coatings, sweeteners, flavorings, and pigments, etc. Those skilled in the art will recognize that other pharmaceutical additives are useful in the present invention. The use of such media and agents for pharmaceutically active substances is well known in the art. The use of any conventional media or agent in the compositions is contemplated, except insofar as such active compounds are incompatible. Additional active compounds may be incorporated into the compositions. Those skilled in the art will recognize that other pharmaceutical additives are useful in the present invention.
[0113] Disclosed herein is a method for treating ACC tumors in patients with hypercortisolism by combined treatment of SGRM treatment and antibody checkpoint inhibitor treatment. In some embodiments, the cancer is a checkpoint inhibitor-sensitive cancer. In some embodiments, the checkpoint inhibitor-sensitive cancer is a GR + It's also cancer.
[0114] Cancer Diagnosis The method is directed to the treatment of patients with adrenal cortical carcinoma (ACC). Cancer is characterized by uncontrolled growth and / or spread of abnormal cells. Typically, a biopsy is taken and cells or tissue from the biopsy are examined under a microscope to confirm the suspected condition. In some cases, further tests need to be performed on the cells' proteins, DNA, and RNA to verify the diagnosis.
[0115] Identifying checkpoint inhibitor-sensitive cancers In some embodiments of the present invention, the method is used to treat patients with at least one checkpoint inhibitor-sensitive cancer. A checkpoint inhibitor-sensitive cancer is one that is responsive to a checkpoint inhibitor, i.e., administration of one or more checkpoint inhibitors can reduce ACC tumor burden or achieve beneficial or desired clinical results related to cancer improvement. For example, administration of the checkpoint inhibitor can cause one or more of the following: reduction in cancer cell count; reduction in tumor size; inhibition (i.e., slowing down to a certain extent and / or stopping) of cancer cell invasion into surrounding organs; inhibition (i.e., slowing down to a certain extent and / or stopping) of tumor metastasis; inhibition (i.e., slowing down to a certain extent and / or stopping) of tumor growth to a certain extent; and / or alleviation to a certain extent of one or more symptoms associated with the disorder; reduction in tumor size; reduction in symptoms resulting from the disease; improvement in the quality of life of those suffering from the disease; reduction in the dose of other medicines required to treat the disease; delay in the progression of the disease; and / or prolongation of the patient's survival.
[0116] Checkpoint inhibitor-sensitive tumors often express high levels of ligands such as PD-L1 and B7, which bind to the checkpoint proteins PD-1 and CTLA-4, respectively. Their interaction suppresses the immune response against tumor cells. In addition to ACC, non-limiting examples of checkpoint inhibitor-sensitive tumors include lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal carcinoma, gastric cancer, esophageal cancer, oral squamous cell carcinoma, head and neck cancer, melanoma, sarcoma, renal cell tumor, hepatocellular tumor, glioblastoma, neuroendocrine tumor, bladder cancer, pancreatic cancer, gallbladder cancer, gastric cancer, prostate cancer, endometrial cancer, thyroid cancer, and mesothelioma.
[0117] (Checkpoint inhibitors) The methods disclosed herein use at least one SGRM in combination with at least one checkpoint inhibitor to treat cancer. In some embodiments, the checkpoint inhibitor is an antibody ("CIA") against at least one checkpoint protein. In some embodiments, the checkpoint inhibitor is a small molecule non-protein compound ("CIC") that blocks an immunosuppressive pathway triggered by one or more checkpoint proteins.
[0118] Checkpoint inhibitor antibodies (also called "CIAs" or "antibody checkpoint inhibitors") In one embodiment, the method of treating cancer comprises administering an SGRM in combination with a checkpoint inhibitor antibody. Such an antibody can block the immunosuppressive activity of the checkpoint protein. A number of such antibodies, for example, antibodies against PD-1, CTLA4, and PD-L1, have already been shown to be effective in treating cancer.
[0119] Anti-PD-1 antibodies have been used to treat melanoma, non-small cell lung cancer, bladder cancer, prostate cancer, colon cancer, head and neck cancer, triple-negative breast cancer, leukemia, lymphoma, and renal cell carcinoma. Exemplary anti-PD-1 antibodies include lambrolizumab (MK-3475, MERCK), nivolumab (BMS-936558, BRISTOL-MYERS SQUIBB), AMP-224 (MERCK), and pidilizumab (CT-011, CURETECH LTD.).
[0120] Anti-CTLA4 antibodies have been used in clinical trials for the treatment of melanoma, prostate cancer, small cell lung cancer, and non-small cell lung cancer. A notable feature of anti-CTLA4A is the kinetics of anti-tumor effects, which require a lag period of up to 6 months for physiological response after initial treatment. In some cases, tumors may actually increase in size after treatment begins before shrinkage is observed (Pardoll, 2012, Nature Reviews Cancer 12:252-264). Exemplary anti-CTLA4CIA include ipilimumab (Bristol-Myers Squibb) and tremelimumab (PFIZER).
[0121] For example, CIA against other checkpoint proteins such as LAG-3 (lymphocyte activation gene 3), B7-H3 (B7 homolog 3 protein), B7-H4 (B7 homolog 4 protein), TIM-3 (T cell immunoglobulin and mucin domain 3), CD160, CD244, VISTA (V domain Ig inhibitor of T cell activation), TIGIT (T cell immunoglobulin and ITIM domain), and BTLA (B cell and T cell lymphocyte attenuator) may also be used in combination with the SGRMs disclosed herein to treat cancer. For example, antibodies that inhibit LAG-3 include IMP321 / Eftilagimod alpha (Immutep), Relatlimab (BMS-986016, Bristol Myers Squibb (BMS)), LAG525 (Novartis), and MK-4280 (Merck). Antibodies that inhibit B7-H3 include Enoblituzumab / MGA271 (MacroGenics), MGD009 e (MacroGenics), 131 I-8H9 / omburtamab (Y-mAbs), and 124I-8H9 / omburtamab (Y-mAbs). Antibodies that block TIM-3 include LY3321367 (also known as LY332; Eli Lilly and Company), TSR-022 (Tesaro), MBG453 (Novartis), Sym023 (Symphogen), INCAGN2390 (Incyte), BMS-986258 (BMS), RO7121661 (Roche), and SHR-1702 (Jiangsu HengRui), of which LY3321367 has shown promise in early clinical trials, including in combination with PD-L1 checkpoint inhibitors. Antibodies that block VISTA include JNJ-61610588 (Johnson & Johnson) and CA-170. d (Curis). Antibodies that inhibit TIGIT include MK-7684 (Merck), Tiragolumab / MTIG7192A / RG-6058 (Genentech), Etigilimab / OMP-313M32 (OncoMed), BMS-986207 (BMS), AB-154 (Arcus Biosciences), and ASP-8374 (Potenza).
[0122] The CIA used in the present disclosure may be a combination of different CIAs, especially when the target checkpoint proteins, e.g., PD-1 and CTLA4, suppress the immune response through different signaling pathways. A combination of multiple CIAs against any of the checkpoint proteins or a single CIA against both checkpoint proteins may provide an improved immune response.
[0123] (CIA Creation) CIA can be expressed using methods well known in the art. See, for example, Kohler and Milstein, Nature 256:495 (1975), and Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL.1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991). Monoclonal antibodies can be obtained by injecting a mouse with an antigen, such as a checkpoint protein or a composition containing an epitope thereof, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma culture.
[0124] The monoclonal antibodies produced can be isolated and purified from the hybridoma culture by a variety of established techniques. Such isolation techniques include affinity chromatography with protein-A sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3. See also Baines et al., "Purification of Immunoglobulin G (IgG)" in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992). After initial development of antibodies to checkpoint proteins, the antibodies can be sequenced and then prepared by recombinant techniques. Humanization and chimerization of mouse antibodies and antibody fragments are well known to those skilled in the art. See, e.g., Leung et al. Hybridoma 13:469 (1994); U.S. Patent Application Publication No. 20140099254A1.
[0125] Human antibodies can be produced using transgenic mice that have been genetically engineered to produce specific human antibodies in response to challenge with checkpoint proteins. See Green et al., Nature Genet. 7:13 (1994); Lonberg et al., Nature 368:856 (1994). Human antibodies against checkpoint proteins can also be constructed by genetic or chromosomal transfection methods, phage display techniques, or in vitro activated B cells. See, e.g., McCafferty et al., 1990, Nature 348:552-553; U.S. Patent Nos. 5,567,610 and 5,229,275.
[0126] (CIA modification) CIAs can also be produced by introducing conservative modifications to existing CIAs. For example, modified CIAs can contain heavy and light chain variable regions and / or Fc regions that are homologous to counterparts of the antibodies produced above. Modified CIAs that can be used in the methods disclosed herein must retain the desired functional property of being able to block checkpoint signaling pathways.
[0127] CIAs can also be produced by modifying protein modification sites. For example, glycosylation sites of antibodies can be modified to produce antibodies lacking glycosylation, and such modified CIAs typically increase the affinity of the antibody to the antigen. Antibodies can also be PEGylated by reacting with polyethylene glycol (PEG) under conditions that result in one or more PEG groups being attached to the antibody. PEGylation can increase the biological half-life of the antibody. Antibodies with such modifications can also be used in combination with selective GR modulators disclosed herein, so long as they retain the desired functional property of blocking checkpoint pathways.
[0128] iii. Evaluation of the functional properties of candidate checkpoint inhibitors A number of well-known assays can be used to assess whether a candidate, i.e., an antibody raised by immunizing an animal with an antigen comprising a checkpoint protein, an epitope of a checkpoint protein, or a test compound from a combinatorial library, as disclosed above, is an antibody checkpoint inhibitor. Non-limiting example assays include binding assays (e.g., enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA)), fluorescence-activated cell sorting (FACS) analysis, cell-based assays, and in vivo assays.
[0129] Binding Assay In some embodiments, the assay is a direct binding assay. The checkpoint protein can be coupled with a radioisotope or enzyme label such that binding of the checkpoint protein and the candidate can be measured by detecting the labeled checkpoint protein in a complex. For example, a checkpoint protein can be coupled with 125 I, 35 S, 14 C, or 3 Candidates can be labeled either directly or indirectly with H, and such radioisotopes are detected by direct counting of radioactive emission or by scintillation counting. Determining the ability of candidates to bind to their cognate checkpoint proteins can be accomplished, for example, by measuring direct binding. Alternatively, checkpoint protein molecules can be enzymatically labeled, for example, with horseradish peroxidase, alkaline phosphatase, or luciferase, and binding of the candidate to the target checkpoint protein is determined by conversion of an appropriate substrate to product.
[0130] Enzyme-linked immunosorbent assays (ELISAs) are commonly used to assess the binding specificity of CIA candidates to their target checkpoint proteins. In a typical assay, microtiter plates are coated with checkpoint proteins by coating overnight at 37° C. with 5 μg / ml of checkpoint protein. Serum samples containing candidate CIAs are diluted in PBS, 5% serum, 0.5% Tween-20 and incubated in the wells for 1 h at room temperature, followed by the addition of anti-human IgG Fc and IgG F(ab')-horseradish peroxidase in the same diluent. After 1 h at room temperature, enzyme activity is assessed by the addition of ABTS substrate (Sigma, St. Louis Mo.) and read at 415-490 nm after 30 min.
[0131] The binding kinetics (e.g., binding affinity) of the candidates can also be assessed by standard assays known in the art, such as Biacore analysis (Biacore AB, Uppsala, Sweden). In one exemplary assay, purified recombinant human checkpoint proteins are covalently coupled to a CM5 chip (a carboxymethyldextran coated chip) via primary amines using standard amine coupling chemistry and a kit provided by Biacore. Binding is measured by flowing the candidates in HBS EP buffer (provided by Biacore AB) at a concentration of 267 nM at a flow rate of 50 μl / min. Checkpoint protein-candidate association kinetics are followed for 3 minutes and dissociation kinetics are followed for 7 minutes. Association and dissociation curves are fitted to a 1:1 Langmuir binding model using BIA evaluation software (Biacore AB). To minimize the effect of binding forces in estimating the binding constant, only the initial segments of the data corresponding to the association and dissociation phases are used for the fit. The K of the interaction is calculated using the following formula: D , K on and K off A preferred checkpoint inhibitor is one that is more potent than 1×10 -7It can bind to these target checkpoint proteins with a Kd of less than or equal to M.
[0132] For checkpoint proteins that block immune responses through binding to a ligand, further binding assays can be used to test the ability of the candidate to block the binding of the ligand to the checkpoint protein. In one exemplary assay, flow cytometry is used to test the blocking of the binding of a ligand (e.g., PD-L1) to a checkpoint protein (e.g., PD-1) expressed in transfected CHO cells. Various concentrations of the candidate are added to a suspension of cells expressing the checkpoint protein and incubated at 4°C for 30 minutes. Unbound inhibitors are washed away, and FITC-labeled ligand protein is added to the tube and incubated at 4°C for 30 minutes. FACS analysis is performed using a FACScan flow cytometer (Becton Dickinson, San Jose, Calif.). The mean fluorescence intensity (MFI) of the staining of the cells indicates the amount of ligand that binds to the checkpoint protein. A reduced MFI in the sample spiked with the candidate indicates that the candidate is effective in blocking the binding of the ligand to the target checkpoint protein.
[0133] For example, a homogeneous time-resolved fluorescence (HTRF) binding assay, as described in PCT Publication WO2015034820, may also be used to assay the ability of the candidate to block checkpoint protein-ligand interactions. In one embodiment, the CIC used in the above method is an IC measured by a PD-1 / PD-L1 homogeneous time-resolved fluorescence (HTRF) binding assay. 50 A value of 10 pM or less, for example, 0.01 to 10 pM, preferably 1 pM or less, for example, 0.01 to 1 pM, can inhibit PD-1 / PD-L1 interaction.
[0134] (Cell-based assays) In another embodiment, the assay to evaluate whether a candidate is a checkpoint inhibitor is a cell-based assay. The mixed lymphocyte reaction (MLR) assay, described in U.S. Pat. No. 8,008,449, is routinely used to measure T cell proliferation, IL-2 and / or IFN-γ production. In one exemplary assay, human T cells are transfected with human CD4 + Candidates are purified from PBMCs using T cell enrichment columns (R&D systems). Candidates are added to multiple T cell cultures at different concentrations. The cells are cultured at 37°C for 5 days and 100 μl of medium is taken from each culture for cytokine measurement. IFN-gamma and other cytokine levels are measured using OptEIA ELISA kits (BD Biosciences). The cells are cultured at 37°C for 5 days and 100 μl of medium is taken from each culture for cytokine measurement. IFN-gamma and other cytokine levels are measured using OptEIA ELISA kits (BD Biosciences). 3 The cells are labeled with H-thymidine, cultured for an additional 18 hours, and analyzed for cell proliferation. Results showing that cultures containing the candidate exhibit increased T cell proliferation, increased production of IL-2 and / or IFN-gamma compared to controls indicate that the candidate is effective in inhibiting a checkpoint protein of the T cell immune response.
[0135] In vivo assay In another embodiment, the assay used to evaluate whether a candidate is a checkpoint inhibitor is an in vivo assay. In one exemplary assay, 6-8 week old female AJ mice (Harlan Laboratories) are randomized into 6 groups by weight. On day 0, the mice are injected with 2×10 mAbs dissolved in 200 μl of DMEM medium into the right flank. 6 of SA1 / N fibrosarcoma cells are implanted subcutaneously. The mice are treated with PBS vehicle or the candidate at the indicated dosage. The animals are dosed by intraperitoneal injection with approximately 200 μl of PBS containing the candidate or vehicle on days 1, 4, 8, and 11. The mice are monitored twice weekly for tumor growth for approximately 6 weeks. The tumors are measured three-dimensionally (height x width x length) using electronic calipers, and tumor volume is calculated. The tumors are then allowed to grow to the tumor endpoint (1500 mm 3Mice are euthanized when the tumor reaches a volume below 1500 mm or when the mice exhibit greater than 15% weight loss. 3 Results showing a longer mean time to reach CR2+ / CR4 indicates that the candidate has activity in inhibiting cancer growth.
[0136] (Glucocorticoid receptor modulators (GRM)) In general, treatment of adrenocortical carcinoma (ACC) in patients with glucocorticoid excess can be achieved by administering an effective amount of a selective glucocorticoid receptor modulator (SGRM) having a fused azadecalin structure, a heteroaryl-ketone fused azadecalin structure, or an octahydro fused azadecalin structure, and an antibody checkpoint inhibitor. In some embodiments, the antibody checkpoint inhibitor is effective against cells and tumors expressing one or more of the PD-1 antigen, CTLA-4 antigen, PD-L1 antigen, or PD-L2 antigen. In some embodiments, a cancer chemotherapeutic agent may be administered. The cancer chemotherapeutic agent may be selected from, for example, taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducers, antimetabolites, mitotic inhibitors, and combinations thereof.
[0137] Selective glucocorticoid receptor modulator (SGRM) compounds include compounds that contain heteroaryl-ketone fused azadecalin structure (sometimes referred to as heteroaryl-ketone fused azadecalin backbone).Exemplary SGRM compounds that contain heteroaryl-ketone fused azadecalin structure include those described in U.S. Patent Nos. 8,859,774; 9,273,047; 9,707,223; and 9,956,216.All patents, patent publications, and patent applications disclosed herein are incorporated herein by reference in their entirety.
[0138] In some cases, the GRM backbone is a fused azadecalin. In some cases, the GRM having a fused azadecalin backbone is an SGRM, which may be a GRA or an SGRA. In some cases, the fused azadecalin is a compound having the formula:
[0139] [ka]
[0140] During the ceremony, L 1 and L 2 is a member independently selected from a bond and unsubstituted alkylene; R 1 is unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, -OR 1A , N.R. 1C R 1D , -C(O)NR 1C R 1D , and -C(O)OR 1A where R 1A is a member selected from hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl; R 1C and R 1D are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl, optionally joined together to form an unsubstituted ring together with the nitrogen to which they are attached, said ring optionally containing an additional ring nitrogen; R 2 has the formula:
[0141] [ka]
[0142] During the ceremony, R 2G is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, -CN, and -CF3; J is phenyl; t is an integer from 0 to 5; X is -S(O2)-; R 5 is 1 to 5 R 5A phenyl optionally substituted with a group; R 5A is hydrogen, halogen, -OR 5A1 , S(O2)NR 5A2 R 5A3 , -CN, and unsubstituted alkyl; R 5A1 is a member selected from hydrogen and unsubstituted alkyl; R 5A2 and R 5A3 is a member independently selected from hydrogen and unsubstituted alkyl. Examples of such compounds include those disclosed in US Pat. No. 7,928,237 and US Pat. No. 8,461,172, both of which are incorporated herein by reference in their entireties.
[0143] In one embodiment, the fused azadecalin SGRM is CORT108297, i.e., (R)-(4a-ethoxymethyl-1-(4-fluorophenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1H,1,2,6-triaza-cyclopenta[b]naphthalene, having the following structure:
[0144] [ka]
[0145] In some cases, the GRM backbone is a heteroaryl ketone-fused azadecalin or an octahydro-fused azadecalin. In some cases, a GRM having a heteroaryl ketone-fused azadecalin backbone or an octahydro-fused azadecalin backbone is an SGRM, which may be a GRA or an SGRA.
[0146] Exemplary GRMs containing heteroaryl ketone-fused azadecalin structures include those disclosed in U.S. Patent No. 8,859,774, which can be prepared as disclosed therein, and which is incorporated herein by reference in its entirety. Such exemplary GRMs may be SGRMs. In some cases, the GRMs containing heteroaryl ketone-fused azadecalin structures have the following structure, or a salt or isomer thereof:
[0147] [ka]
[0148] During the ceremony, R 1 has 5 to 6 ring members and 1 to 4 heteroatoms, each independently selected from the group consisting of N, O, and S, and optionally each independently R 1a is a heteroaryl ring substituted with 1 to 4 groups selected from R 1a are independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, CN, N-oxide, C 3-8 Cycloalkyl and C 3-8 heterocycloalkyl; Ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring, and a heteroaryl ring, the heterocycloalkyl ring and the heteroaryl ring having 5 to 6 ring members and 1 to 4 heteroatoms each independently selected from the group consisting of N, O, and S; R 2 are independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl-C 1-6 Alkoxy, -CN, -OH, -NR 2a R2b , -C(O)R 2a , -C(O)OR 2a , -C(O)NR 2a R 2b , -SR 2a , -S(O)R 2a , -S(O)2R 2a , C 3-8 Cycloalkyl and C 3-8 heterocycloalkyl, wherein the heterocycloalkyl group is selected from the group consisting of 1 to 4 R 2c optionally substituted with a group; Or, two R attached to the same carbon 2 groups combine to form an oxo group (=O); Or, two R 2 groups combine to form a heterocycloalkyl ring having 5-6 ring members and 1-3 heteroatoms each independently selected from the group consisting of N, O, and S, wherein the heterocycloalkyl ring optionally contains 1-3 R 2d is substituted with a group; R 2a and R 2b are each independently hydrogen and C 1-6 selected from the group consisting of alkyl; R 2c are each independently hydrogen, halogen, hydroxy, or C 1-6 Alkoxy, C 1-6 Haloalkoxy, -CN, and -NR 2a R 2b selected from the group consisting of; R 2d are each independently hydrogen and C 1-6 alkyl, or two R attached to the same ring atom 2d The groups combine to form (=O); R 3 Each has 1 to 4 R 3a phenyl and pyridyl, optionally substituted with a group; R 3a are each independently hydrogen, halogen, or C 1-6haloalkyl; The subscript n is an integer from 0 to 3.
[0149] In some cases, the heteroaryl-ketone fused azadecalin GRM is relacorilant (CORT125134), i.e., (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, having the following structure:
[0150] [ka]
[0151] In one embodiment, the heteroaryl-ketone fused azadecalin SGRM is the compound (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1-H-pyrazoloP,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone (referred to as "CORT113176"), having the following structure:
[0152] [ka]
[0153] Exemplary GRMs that include an octahydro-fused azadecalin structure include compounds disclosed in U.S. Patent No. 10,047,082, which is incorporated herein by reference in its entirety. In certain embodiments, the octahydro-fused azadecalin GRM has the formula:
[0154] [ka]
[0155] During the ceremony, R 1 has 5 to 6 ring members and 1 to 4 heteroatoms, each independently selected from the group consisting of N, O, and S, and optionally R 1a is a heteroaryl ring substituted with 1 to 4 groups selected from R 1a are independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, N-oxide, and C 3-8 cycloalkyl; Ring J is selected from the group consisting of aryl and heteroaryl rings having 5-6 ring members and 1-4 heteroatoms, each independently selected from the group consisting of N, O, and S; R 2 are each independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl-C 1-6 Alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , S.R. 2a , S(O)R 2a , S(O)2R 2a , C 3-8 Cycloalkyl and C having 1 to 3 heteroatoms each independently selected from the group consisting of N, O, and S 3-8 heterocycloalkyl; Alternatively, two R on adjacent ring atoms 2 The groups, in combination, have 5 to 6 ring members and 1 to 3 heteroatoms, each independently selected from the group consisting of N, O, and S, and optionally 1 to 3 R 2cforming a heterocycloalkyl ring substituted with a group; R 2a , R 2b , and R 2c are each independently hydrogen and C 1-6 selected from the group consisting of alkyl; R 3a are each independently a halogen; The subscript n is an integer from 0 to 3.
[0156] In some cases, the octahydro-fused azadecalin GRM is CORT125281, i.e., ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, having the following structure:
[0157] [ka]
[0158] (Identification of selective glucocorticoid receptor modulators (SGRMs)) To determine whether a test compound is an SGRM, the compound is first subjected to an assay that measures its ability to bind to GR and inhibit GR-mediated activity to determine whether the compound is a glucocorticoid receptor modulator. If the compound is identified as a glucocorticoid receptor modulator, the compound is then subjected to a selectivity test to determine whether the compound can specifically bind to GR when compared to proteins other than GR, such as estrogen receptor, progesterone receptor, androgen receptor, or mineralocorticoid receptor. In some embodiments, the SGRM binds to GR with a significantly higher affinity, for example at least 10-fold higher affinity, than to proteins other than GR. The SGRM may exhibit 100-fold, 1000-fold, or more selectivity in binding to GR compared to proteins other than GR.
[0159] connectivity The binding of a test compound to the glucocorticoid receptor can be measured using various assays, for example, by screening the test compound for its competitive binding to the glucocorticoid receptor with a glucocorticoid receptor ligand, such as dexamethasone. Those skilled in the art will recognize that there are several methods for carrying out such competitive binding assays. In some embodiments, the glucocorticoid receptor is pre-incubated with a labeled glucocorticoid receptor ligand and then contacted with the test compound. This type of competitive binding assay is sometimes referred to as a binding displacement assay. A decrease in the amount of labeled ligand bound to the glucocorticoid receptor indicates that the test compound is bound to the glucocorticoid receptor. In some cases, the labeled ligand is a fluorescently labeled compound (e.g., a fluorescently labeled steroid or steroid analog). Alternatively, the labeled test compound can be used to directly measure the binding of the test compound to the glucocorticoid receptor. This latter type of assay is called a direct binding assay.
[0160] Both direct and competitive binding assays can be used in a variety of formats. These formats can be similar to those used in immunoassays and receptor binding assays. For descriptions of various formats of binding assays, including competitive and direct binding assays, see Basic and Clinical Immunology, 7th Edition (D. Stites and A. Terr (Eds.), 1991; Enzyme Immunoassay, ET Maggio (Ed.), CRC Press, Boca Raton, Fla. (1980); and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers BV, Amsterdam (1985), each of which is incorporated herein by reference.
[0161] For example, in a solid-phase competitive binding assay, a sample compound can compete with a labeled analyte for specific binding sites on a binding agent bound to a solid surface.In this type of format, the labeled analyte can be a glucocorticoid receptor ligand, and the binding agent can be a glucocorticoid receptor bound to a solid phase.Alternatively, the labeled analyte can be a labeled glucocorticoid receptor, and the binding agent can be a solid-phase glucocorticoid receptor ligand.The concentration of the labeled analyte bound to the capture agent is inversely proportional to the competitive ability of the test compound in the binding assay.
[0162] Alternatively, competitive binding assays may be performed in liquid phase, and any of a variety of techniques known in the art may be used to separate bound from unbound labeled protein. For example, several methods have been developed to distinguish between bound and excess bound ligands, or between bound and excess unbound test compounds. These methods involve identification of bound complexes by sucrose gradient centrifugation, gel electrophoresis, or gel isoelectric focusing; precipitation of receptor-ligand complexes with protamine sulfate or adsorption onto hydroxylapatite; and removal of unbound compounds or ligands by adsorption onto dextran-coated charcoal (DCC) or binding to immobilized antibodies. After separation, the amount of bound ligand or test compound is determined.
[0163] Alternatively, homogeneous binding assays may be performed that do not require a separation step. For example, the label on the glucocorticoid receptor may be altered by the binding of the glucocorticoid receptor to its ligand or test compound. This change in the labeled glucocorticoid receptor will result in a decrease or increase in the signal emitted by the label, allowing detection or quantification of the bound glucocorticoid receptor by measuring the label at the end of the binding assay. A wide variety of labels can be used. The components may be labeled by any of several methods. Useful radioactive labels include: 3 H, 125 I, 35 S, 14 C, or 32Useful non-radioactive labels include those incorporating P. Useful non-radioactive labels include those incorporating fluorophores, chemiluminescent materials, phosphorescent materials, electrochemiluminescent materials, and the like. Fluorescent materials are particularly useful in analytical methods used to detect shifts in protein structure, such as fluorescence anisotropy and / or fluorescence polarization. The choice of label is based on the required sensitivity, ease of binding to the compound, stability requirements, and available instrumentation. For a review of various labeling or signal generating systems that can be used, see U.S. Pat. No. 4,391,904, which is incorporated herein by reference in its entirety for all purposes. The label can be directly or indirectly attached to the desired component of the assay according to methods well known in the art. Optionally, the test compound is contacted with GR in the presence of a fluorescently labeled ligand (e.g., a steroid or steroid analog) with known affinity for GR, and the amount of bound and free labeled ligand is estimated by measuring the fluorescence polarization of the labeled ligand.
[0164] HepG2 tyrosine aminotransferase (TAT) assay Compounds that exhibit the desired binding affinity to GR are tested for their activity in inhibiting GR-mediated activity. Typically, these compounds are subjected to a tyrosine aminotransferase assay (TAT assay), which evaluates the ability of a test compound to inhibit the induction of tyrosine aminotransferase activity by dexamethasone. See Example 1. GR modulators suitable for the methods disclosed herein have IC 50 (50% inhibitory concentration) is less than 10 micromolar. Other assays, including but not limited to those described below, can also be used to confirm the GR modulating activity of the compounds.
[0165] Cell-Based Assays Cell-based assays using whole cells or cell fractions containing glucocorticoid receptors can also be used to measure the binding ability of test compounds or their ability to modulate glucocorticoid receptor activity. Exemplary cell types that can be used in the methods of the present invention include any mammalian cell, including, for example, leukocytes (such as neutrophils, monocytes, macrophages, eosinophils, basophils, mast cells, and lymphocytes such as T cells and B cells), leukemia cells, Burkitt's lymphoma cells, tumor cells (including mouse mammary tumor virus cells), endothelial cells, fibroblasts, cardiac cells, muscle cells, breast tumor cells, ovarian cancer carcinomas, cervical cancer, glioblastomas, hepatocytes, kidney cells, and neuronal cells, as well as fungal cells, including yeast. The cells can be primary cells, or tumor cells or other types of immortal cell lines. Of course, glucocorticoid receptors can be expressed in cells that do not express endogenous glucocorticoid receptors.
[0166] In some cases, in addition to protein fusions, fragments of the glucocorticoid receptor can also be used for screening. If a molecule that competes with the glucocorticoid receptor ligand in binding is desired, the GR fragment used is a fragment that can bind to the ligand (e.g., dexamethasone). Alternatively, any GR fragment can be used as a target to identify molecules that bind to the glucocorticoid receptor. Glucocorticoid receptor fragments can include any fragment of the glucocorticoid receptor, for example, at least 20, at least 30, at least 40, at least 50 amino acids, up to a protein that contains all but one amino acid.
[0167] In some embodiments, the reduction of signal transduction triggered by glucocorticoid receptor activation is utilized to identify glucocorticoid receptor modulators. Glucocorticoid receptor signal transduction activity can be measured in many ways. For example, downstream molecular events can be monitored to measure signal transduction activity. Downstream events include activation or expression resulting from glucocorticoid receptor stimulation. Exemplary downstream events useful in functional evaluation of transcriptional activation and antagonism in intact cells include increased expression of several glucocorticoid response element (GRE)-dependent genes (PEPCK, tyrosine aminotransferase, aromatase). In addition, certain cell types susceptible to GR activation may be used, such as osteocalcin expression in osteoblasts, which is downregulated by glucocorticoids; primary hepatocytes, which show glucocorticoid-mediated increased expression of PEPCK and glucose-6-phosphate (G-6-Pase). GRE-mediated gene expression has also been demonstrated in transfected cell lines using well-known GRE regulatory sequences (e.g., mouse mammary tumor virus promoter (MMTV) transfected upstream of a reporter gene construct). Examples of useful reporter gene constructs include luciferase (luc), alkaline phosphatase (ALP), and chloramphenicol acetyltransferase (CAT). Functional evaluation of transcriptional repression can be performed in cell lines such as monocytes or human dermal fibroblasts. Useful functional assays include those that measure IL-1β-stimulated IL-6 expression in transfected cell lines; those that measure reduced expression of collagenase, cyclooxygenase-2, and various chemokines (MCP-1, RANTES); those that measure LPS-stimulated cytokine release (e.g., TNFα); or those that measure expression of genes controlled by NFkB or AP-1 transcription factors.
[0168] Compounds tested in whole-cell assays may also be tested in cytotoxicity assays. Cytotoxicity assays are used to determine the extent to which a detected effect is due to cellular effects other than glucocorticoid receptor binding. In an exemplary embodiment, the cytotoxicity assay involves contacting constitutively active cells with the test compound. Any reduction in cellular activity is indicative of a cytotoxic effect.
[0169] 3) Additional Assays Further illustrative of the many assays that can be used to validate the compositions used in the methods of the present invention are in vivo assays based on glucocorticoid activity. For example, an assay can be used to evaluate the ability of putative GR modulators to inhibit the incorporation of 3H-thymidine into DNA in cells stimulated by glucocorticoids. Alternatively, putative GR modulators can compete with 3H-dexamethasone in binding to hepatoma tissue culture GR (see, for example, Choi et al., Steroids, vol. 57: pp 313-318, 1992). As another example, putative GR modulators can be used to block the nuclear binding of 3H-dexamethasone-GR complex (Alexandrova et al., J. Steroid Biochem. Mol. Biol, vol. 41: pp 723-725, 1992). For further validation of putative GR modulators, a kinetic assay can be used that can distinguish between glucocorticoid agonists and modulators by receptor binding kinetics (described in Jones, Biochem J., 204:721-729, 1982).
[0170] In another illustrative example, to confirm anti-glucocorticoid activity, the assay described in Daune, Molec. Pharm., vol. 13: pp 948-955, 1977; and U.S. Patent No. 4,386,085 can be used. Briefly, thymocytes from adrenalectomized rats are incubated in nutrient medium containing dexamethasone and various concentrations of a test compound (a putative GR modulator). 3 H-uridine is added to cell cultures, further incubation is performed, and the incorporation of the radiolabel into polynucleotides is measured. 3 It reduces the amount of H-uridine, i.e. GR modulators counter this effect.
[0171] iii.Selectivity The GR modulator selected above is then subjected to a selectivity assay to determine whether it is an SGRM. Typically, the selectivity assay involves testing the compound that binds to the glucocorticoid receptor for the degree of binding to a protein other than the glucocorticoid receptor in vitro. The selectivity assay may be performed in vitro or in a cell-based system as described above. The binding test may be performed on any suitable protein other than the glucocorticoid receptor, including antibodies, receptors, enzymes, and the like. In an exemplary embodiment, the binding protein other than the glucocorticoid receptor is a cell surface receptor or a nuclear receptor. In another exemplary embodiment, the protein other than the glucocorticoid receptor is a steroid receptor, such as an estrogen receptor, a progesterone receptor, an androgen receptor, or a mineralocorticoid receptor.
[0172] The selectivity of an antagonist for GR compared to MR can be measured using various assays known to those skilled in the art. For example, specific antagonists can be identified by measuring the binding ability of the antagonist to GR compared to MR (see, e.g., U.S. Pat. Nos. 5,606,021; 5,696,127; 5,215,916; and 5,071,773). Such analysis can be performed using direct binding assays or by evaluating competitive binding to purified GR or purified MR in the presence of known ligands. In an exemplary assay, cells stably expressing high levels of glucocorticoid receptor or mineralocorticoid receptor (see, e.g., U.S. Pat. No. 5,606,021) are used as a source of purified receptor. The affinity of the ligand for the receptor is then measured directly. GR modulators that show at least 10-fold, 100-fold, and often 1000-fold higher affinity for GR compared to MR are then selected for use in the methods of the present invention.
[0173] Selectivity assays may include quantification of the ability to inhibit GR-mediated activity but not MR-mediated activity. One way to identify such GR-specific modulators is to assess the ability of antagonists to prevent the activation of a reporter construct using a transfection assay (see, for example, Bocquel et al., J. Steroid Biochem Molec. Biol., vol. 45: pp. 205-215, 1993; U.S. Pat. Nos. 5,606,021 and 5,929,058). In an exemplary transfection assay, an expression plasmid encoding the receptor and a reporter plasmid containing a reporter gene linked to a receptor-specific regulatory element are cotransfected into suitable receptor-negative host cells. The transfected host cells are then cultured in the presence and absence of a hormone, such as cortisol or an analog thereof, that can activate the hormone-responsive promoter / enhancer element of the reporter plasmid. The transfected and cultured host cells are then monitored for induction of the production (i.e., presence) of the reporter gene sequence. Finally, the expression and / or steroid binding capacity of the hormone receptor protein (encoded by the receptor DNA sequence on the expression plasmid and produced in the transfected and cultured host cells) is measured by determining the activity of the reporter gene in the presence and absence of an antagonist. The antagonist activity of the compound may be determined in comparison with known antagonists of the GR and MR receptors (see, for example, U.S. Pat. No. 5,696,127). The potency is then reported as the percent maximal response observed for each compound relative to the reference antagonist compound. GR modulators that show at least 100-fold, and often 1000-fold or more, activity against GR compared to MR, PR, or AR are selected for use in the methods disclosed herein.
[0174] Pharmaceutical Compositions and Administration i. Preparation In some embodiments, the present invention provides pharmaceutical compositions comprising a pharma- ceutical excipient and an SGRM, and pharmaceutical compositions comprising a pharma-ceutical excipient and a CIC or a CIA.
[0175] Any of the SGRMs, CICs, or CIAs disclosed herein can be formulated with a pharma- ceutically acceptable carrier. Such compositions may contain one or a combination (e.g., two or more different) of the antibodies, or immunoconjugates or bispecific molecules of the present invention. For example, a pharmaceutical composition of the present invention can contain a combination of antibodies (or immunoconjugates or bispecific molecules) that bind to different epitopes on a target antigen or have complementary activities.
[0176] In one embodiment, the present invention provides a pharmaceutical composition for treating an ACC patient with hypercortisolism, the pharmaceutical composition comprising a pharma- ceutical composition comprising a pharma- ceutical excipient and a GRM. In some embodiments, the pharmaceutical composition comprises a pharma- ceutical excipient and a SGRM. In a preferred embodiment, the pharmaceutical composition comprises a pharma- ceutical excipient and a nonsteroidal SGRM.
[0177] GRMs and SGRMs (as used herein, GRMs and SGRMs include nonsteroidal GRMs and nonsteroidal SGRMs) can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. Oral preparations are preferred. Oral preparations include tablets, pills, powders, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, and the like suitable for ingestion by a patient. GRMs and SGRMs can also be administered by injection, i.e., intravenously, intramuscularly, intradermally, subcutaneously, intraduodenally, or intraperitoneally. GRMs and SGRMs can also be administered by inhalation, e.g., intranasally. Additionally, GRMs and SGRMs can be administered transdermally. Thus, the present invention also provides pharmaceutical compositions comprising a pharma- ceutically acceptable carrier or excipient and a GRM or SGRM.
[0178] For preparing pharmaceutical compositions from GRMs and SGRMs, pharma- ceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or encapsulating materials. Details concerning techniques for formulation and administration are well described in the scientific and patent literature, see, for example, the latest edition of Remington's Pharmaceutical Sciences, Mack Publishing Co, Easton PA ("Remington's").
[0179] In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient, GRM or SGRM. In tablets, the active ingredient is mixed with the carrier having the required binding properties in suitable proportions and compacted in the shape and size desired.
[0180] The powders and tablets preferably contain 5% to 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. The term "preparation" is intended to include formulations of the active compound together with an encapsulating material as a carrier to form an capsule, in which the active ingredient, with or without other carriers, is enclosed by the carrier, thereby bringing them together. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
[0181] Suitable solid additives are carbohydrate or protein fillers, including, but not limited to, sugars, including lactose, sucrose, mannitol, or sorbitol; starches derived from corn, wheat, rice, potato, or other plants; celluloses, such as methylcellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as cross-linked polyvinylpyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
[0182] Dragee cores are provided with suitable coatings such as gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and concentrated sugar solutions that may contain suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the amount of active compound (i.e., dosage). The pharmaceutical preparations of the present invention may also be used orally using push-fit capsules, for example made of gelatin, as well as soft sealed capsules made of gelatin and a coating, for example, glycerol or sorbitol. Push-fit capsules may contain the GR modulator mixed with a filler or binder, such as lactose or starch, a lubricant, such as talc or magnesium stearate, and, optionally, a stabilizer. In soft capsules, such GR modulator compounds may be dissolved or suspended in a suitable liquid, such as fatty acid oils, liquid paraffin, or liquid polyethylene glycol, with or without stabilizers.
[0183] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions.For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
[0184] Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions suitable for oral use may be made by dispersing the finely divided active ingredient in water with viscous materials such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as naturally occurring phospholipids (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearates), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), condensation products of ethylene oxide with partial esters derived from fatty acids and hexitols (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate). The said aqueous suspensions may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, aspartame or saccharin. The osmolarity of the preparation may be adjusted.
[0185] Also included are solid form preparations that are intended to be converted shortly before use into liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active ingredient, colorants, flavorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, and the like.
[0186] Oil suspensions can be formulated by suspending the SGRM in a vegetable oil, such as peanut oil, olive oil, sesame oil, or coconut oil, or a mineral oil, such as liquid paraffin; or a mixture thereof. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners, such as glycerol, sorbitol, or sucrose, can be added to provide a palatable oral preparation. These preparations can be preserved by the addition of an antioxidant, such as ascorbic acid. For examples of injectable oil vehicles, see Minto, J. Pharmacol. Exp. Ther. 281:93-102, 1997. The pharmaceutical formulations of the present invention can also be in the form of oil-in-water emulsions. The oil phase can be a vegetable oil or a mineral oil, or a mixture thereof. Suitable emulsifying agents include naturally occurring gums such as gum acacia and gum tragacanth, naturally occurring phospholipids such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents, as in the formulation of syrups and elixirs. Such formulations may also contain analgesics, preservatives, or coloring agents.
[0187] GRMs and SGRMs are formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. It can be delivered transdermally and topically.
[0188] GRMs and SGRMs may also be delivered as microspheres for sustained release in the body. For example, microspheres may be administered via intradermal injection of drug-containing microspheres for sustained subcutaneous release (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995); as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). Both transdermal and intradermal routes allow constant delivery over a period of weeks or months.
[0189] The pharmaceutical formulations of the present invention may be provided as salts and may be formed with a number of acids, including but not limited to hydrochloric acid, sulfuric acid, acetic acid, lactic acid, tartaric acid, malic acid, succinic acid, and the like. Salts tend to be more soluble in aqueous or other protic solvents than the corresponding free base form. In other cases, the preparations may be lyophilized powders in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol, in a pH range of 4.5-5.5, and combined with a buffer prior to use.
[0190] In another embodiment, the formulations of the present invention can be delivered by using liposomes that fuse with or are incorporated into cell membranes, i.e., by using ligands attached to the liposomes or directly attached to the oligonucleotides that bind to cell surface membrane protein receptors resulting in endocytosis.By using liposomes, it is possible to focus the delivery of GR modulators to target cells in vivo, especially when the liposome surface carries ligands specific to the target cells or otherwise preferentially targets specific organs. (See, for example, Al-Muhammed, J.Microencapsul.13:293-306,1996; Chonn, Curr.Opin.Biotechnol.6:698-708,1995; Ostro, Am.J.Hosp.Pharm.46:1576-1587,1989).
[0191] The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate amounts of the active ingredient, GRM or SGRM. The unit dosage form may be a packaged preparation containing discrete amounts of the preparation, such as packaged tablets, capsules, and powders in vials or ampoules. The unit dosage form may also be a capsule, tablet, cachet, or lozenge itself, or the appropriate number of any of these in packaged form.
[0192] The amount of active ingredient in a unit dose preparation may vary or be adjusted from 0.1 mg to 10,000 mg, more typically from 1.0 mg to 6,000 mg, and most typically from 50 mg to 500 mg. Suitable dosages include about 1 mg, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 mg, depending on the particular application and the potency of the active ingredient. The composition may also contain other compatible therapeutic agents, if desired.
[0193] The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate amounts of the compounds and compositions of the present invention. The unit dosage form can be a packaged preparation containing discrete quantities of the preparation, such as packaged tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, tablet, cachet, or lozenge itself, or the appropriate number of any of these in packaged form.
[0194] The GRM, including the SGRM, can be administered orally. For example, the GRM can be administered as a pill, capsule, or liquid formulation as described herein. Alternatively, the GRM can be provided via parenteral administration. For example, the GRM can be administered intravenously (e.g., by injection or infusion). Further methods of administration of the compounds described herein and pharmaceutical compositions or formulations thereof are described herein.
[0195] In some embodiments, the GRM is administered in one dose. In other embodiments, the GRM is administered in more than one dose, for example, two doses, three doses, four doses, five doses, six doses, seven doses, or more. In some cases, the doses are of equivalent amounts. In other cases, the doses are of different amounts. The doses may increase or decrease over the duration of administration. The amounts vary, for example, according to the properties of the GRM and the characteristics of the patient.
[0196] Any suitable dosage of GRM can be used in the methods disclosed herein. The dosage of GRM administered can be, for example, at least about 100 milligrams (mg) per day, about 150 mg / day, about 200 mg / day, about 250 mg / day, about 300 mg / day, about 350 mg / day, about 400 mg / day, about 450 mg / day, about 500 mg / day, about 550 mg / day, about 600 mg / day, about 650 mg / day, about 700 mg / day, about 750 mg / day, about 800 mg / day, about 850 mg / day, about 900 mg / day, about 950 mg / day, about 1000 mg / day, or more.
[0197] In some cases, an effective amount of a GRM (e.g., an SGRM, such as a nonsteroidal SGRM) is a daily amount of 1-30 mg / kg / day when administered with at least one chemotherapeutic agent, hi some embodiments, the daily amount of the GRM is 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, or 30 mg / kg / day. In some cases, the GRM is administered for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, at least 16 weeks, at least 17 weeks, at least 18 weeks, at least 19 weeks, at least 20 weeks, at least 25 weeks, at least 30 weeks, at least 35 weeks, at least 40 weeks, at least 45 weeks, at least 50 weeks, at least 55 weeks, at least 60 weeks, at least 65 weeks, at least 70 weeks, at least 75 weeks, or at least 80 weeks.
[0198] In some embodiments, the GRM is administered orally. In some embodiments, the GRM is administered in at least one dose. In other words, the GRM can be administered in one, two, three, four, five, six, seven, eight, nine, ten, or more doses. In some embodiments, the GRM is administered orally in one, two, three, four, five, six, seven, eight, nine, ten, or more doses.
[0199] The patient may be administered at least one dose of the GRM, one or more doses, for example, over a period of 2 to 48 hours. In some embodiments, the GRM is administered in a single dose. In other embodiments, the GRM is administered in more than one dose, for example, two doses, three doses, four doses, five doses, or more, over a period of 2 to 48 hours, for example, a 2 hour period, a 3 hour period, a 4 hour period, a 5 hour period, a 6 hour period, a 7 hour period, a 8 hour period, a 9 hour period, a 10 hour period, a 11 hour period, a 12 hour period, a 14 hour period, a 16 hour period, a 18 hour period, a 20 hour period, a 22 hour period, a 24 hour period, a 26 hour period, a 28 hour period, a 30 hour period, a 32 hour period, a 34 hour period, a 36 hour period, a 38 hour period, a 40 hour period, a 42 hour period, a 44 hour period, a 46 hour period, or a 48 hour period. In some embodiments, the GRM is administered over a period of 2-48 hours, 2-36 hours, 2-24 hours, 2-12 hours, 2-8 hours, 8-12 hours, 8-24 hours, 8-36 hours, 8-48 hours, 9-36 hours, 9-24 hours, 9-20 hours, 9-12 hours, 12-48 hours, 12-36 hours, 12-24 hours, 18-48 hours, 18-36 hours, 18-24 hours, 24-36 hours, 24-48 hours, 36-48 hours, or 42-48 hours.
[0200] Single or multiple doses of the formulation may be administered depending on the dosage and frequency required and tolerated by the patient. The formulation may provide a sufficient amount of active agent to effectively treat a disease state. Thus, in certain embodiments, the daily dosage of the pharmaceutical formulation for oral administration of GRM is about 0.01 to about 150 mg per kilogram of body weight per day (mg / kg / day). In some embodiments, the daily dosage is about 1.0 to 100 mg / kg / day, 5 to 50 mg / kg / day, 10 to 30 mg / kg / day, and 10 to 20 mg / kg / day. Lower dosages may be used, particularly when such drugs are administered to anatomically isolated sites such as the cerebrospinal fluid (CSF) space, into the bloodstream, into a body cavity, or into the lumen of an organ, as opposed to oral administration. Substantially higher dosages may be used in local administration. Actual methods for preparing parenterally administrable formulations will be known or apparent to those skilled in the art and are described in more detail in publications such as Remington's (supra). See also Nieman, in "Receptor Mediated Antisteroid Action," Agarwal, et al., eds., De Gruyter, New York (1987).
[0201] The duration of treatment with a GRM or SGRM to treat ACC in patients with excess cortisol can vary depending on the severity of the condition in the subject and the subject's response to the GRM or SGRM. In some embodiments, the GRM and SGRM can be administered for a period of about 1 week to 104 weeks (2 years), more typically about 6 weeks to 80 weeks, and most typically about 9 to 60 weeks. Suitable administration periods also include 5 to 9 weeks, 5 to 16 weeks, 9 to 16 weeks, 16 to 24 weeks, 16 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 weeks, 32 to 52 weeks, 48 to 52 weeks, 48 to 64 weeks, 52 to 64 weeks, 52 to 72 weeks, 64 to 72 weeks, 64 to 80 weeks, 72 to 80 weeks, 72 to 88 weeks, 80 to 88 weeks, 80 to 96 weeks, 88 to 96 weeks, and 96 to 104 weeks. Suitable administration periods also include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 35, 40, 45, 48, 50, 52, 55, 60, 64, 65, 68, 70, 72, 75, 80, 85, 88, 90, 95, 96, 100, and 104 weeks. In general, administration of a GRM or SGRM should be continued until a desired clinically significant reduction or improvement is observed. Treatment with said GRM or SGRM according to the present invention may be sustained for 2 years or even longer.
[0202] In some embodiments, administration of the GRM or SGRM may be stopped for one or more periods, rather than continuously, and then administration may be resumed for one or more periods. Suitable periods for which administration may be stopped include 5-9 weeks, 5-16 weeks, 9-16 weeks, 16-24 weeks, 16-32 weeks, 24-32 weeks, 24-48 weeks, 32-48 weeks, 32-52 weeks, 48-52 weeks, 48-64 weeks, 52-64 weeks, 52-72 weeks, 64-72 weeks, 64-80 weeks, 72-80 weeks, 72-88 weeks, 80-88 weeks, 80-96 weeks, 88-96 weeks, and 96-100 weeks. Suitable periods for which administration will cease also include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 35, 40, 45, 48, 50, 52, 55, 60, 64, 65, 68, 70, 72, 75, 80, 85, 88, 90, 95, 96, and 100 weeks.
[0203] Dosing regimens also take into account pharmacokinetic parameters well known in the art, i.e., rate of absorption, bioavailability, metabolism, clearance, etc. (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51:337-341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J. Pharm. Sci. 84:1144-1146; Rohatagi (1995) Pharmazie 50:610-613; Brophy (1983) Eur. J. Clin. Pharmacol. 24:103-108; Remington, supra, more recently). The clinician, with the aid of state of the art techniques, is able to determine the dosage regimen for each individual patient, GR modulator and disease or condition being treated.
[0204] SGRMs may be used in combination with other active agents known to be useful in modulating the glucocorticoid receptor, or with adjunct agents that may not be effective alone but may contribute to the efficacy of the active agents. The novel methods disclosed herein include administering SGRMs in combination with antibody checkpoint inhibitors.
[0205] In some embodiments, co-administration involves one active agent, GR Co-administration includes administering M or SGRM within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of the second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be achieved by co-formulation, i.e., preparing a single pharmaceutical composition that includes both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active agents and / or adjuncts can be linked or conjugated to each other.
[0206] After the pharmaceutical composition containing the SGRM is formulated in an acceptable carrier, it can be placed in an appropriate container and labeled for treatment of a designated condition. For administration of the GRM or SGRM, such labeling can include, for example, instructions regarding the amount, frequency and method of administration.
[0207] The pharmaceutical compositions of the present invention may be provided as salts and may be formed with a number of acids including, but not limited to, hydrochloric acid, sulfuric acid, acetic acid, lactic acid, tartaric acid, malic acid, succinic acid, and the like. Salts tend to be more soluble in aqueous or other protic solvents than the corresponding free base form. In other cases, the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol, in a pH range of 4.5-5.5, and combined with a buffer prior to use.
[0208] In another embodiment, the compositions of the present invention are useful for parenteral administration, such as intravenous (IV) administration or administration into a cavity or into a cavity of an organ. The preparation for administration may generally comprise a solution of the composition of the present invention dissolved in a pharma- ceutically acceptable carrier. Acceptable vehicles and solvents that may be used include water and Ringer's solution, isotonic sodium chloride. In addition, sterile fixed oils may be conventionally used as a solvent or suspending medium. For this purpose, any sterile fixed oil may be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables as well. These solutions are sterile and generally free of undesirable substances. These preparations may be sterilized by conventional well-known sterilization techniques. The preparations may contain pharma-ceutically acceptable auxiliary substances required for approximate physiological conditions, such as pH adjusting agents and buffers, toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and the like. The concentration of the composition of the present invention in these preparations can vary widely and is selected mainly based on body fluid volume, viscosity, body weight, etc., according to the specific administration form selected and the patient's requirements. For IV administration, the preparation can be a sterile injectable preparation, such as a sterile injectable aqueous or oily suspension. This suspension can be formulated according to known techniques using these suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, such as a solution of 1,3-butanediol.
[0209] ii. Medication Pharmaceutical compositions suitable for administration include compositions containing the active ingredients, such as checkpoint inhibitors and SGRMs, in an amount effective to achieve the intended purpose. The dosage regimen is adjusted to obtain the optimum desired response (e.g., treatment response). For example, a single bolus may be administered, or several divided doses may be administered over a period of time, or the dosage may be reduced or increased in proportion to the exigencies of the treatment situation. It is particularly advantageous to formulate parenteral compositions into unit dosage forms for ease of administration and uniformity of dosage. Unit dosage form, as used herein, refers to a physically discrete unit suitable as a unitary dosage for a subject to be treated; each unit contains a predetermined amount of active compound calculated to produce the desired treatment effect, together with the necessary pharmaceutical carrier. The specifications of the unit dosage forms of the present invention are determined by and directly depend on (a) the unique characteristics of the active compound and the specific treatment effect to be achieved, and (b) the inherent limitations in the art of compounding such active compounds to treat sensitivities in individuals.
[0210] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention may be varied to obtain an amount of the active ingredient effective to achieve the desired therapeutic response in a particular patient, composition, and mode of administration, without causing toxicity to the patient. The selection of the dosage level will depend on a variety of factors, including, for example, the activity of the particular composition of the present invention used, or its esters, salts, or amides, the pharmacokinetics of said composition, the route of administration, the timing of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular composition used, the age, sex, weight, condition, overall health, and medical history of the patient being treated, and similar factors well known in the medical arts.
[0211] The pharmaceutical composition of the present invention is preferably in unit dose form. In such form, the preparation is divided into unit doses containing an appropriate amount of active ingredient, GRM (e.g., SGRM), or antibody checkpoint inhibitor. This unit dose form can be a packaged preparation, the package containing a discrete amount of preparation, for example, a tablet, capsule, and powder packaged in a vial or ampoule. Also, the unit dose form can be a capsule, tablet, cachet, or lozenge itself, or the appropriate number of any of these packaged forms.
[0212] The dosing regimen for a checkpoint inhibitor or GRM (e.g., SGRM) also takes into account pharmacokinetic parameters well known in the art, i.e., absorption rate, bioavailability, metabolism, clearance, etc. (see, e.g., Hidalgo-Aragones (1996), J. Steroid. Biochem. Mol. Biol., 58: pp 611-617; Groning (1996), Pharmazie, 51: pp 337-341; Fotherby (1996), Contraception, 54: pp 59-69; Johnson (1995), J. Pharm. Sci., 84: pp 1144-1146; Rohatagi (1995), Pharmazie, 50: pp 610-613; Brophy (1983), Eur. J. Clin. Pharmacol., 24: pp 103-108; see Remington's, latest edition above). The current state of the art allows the clinician to determine the dosing regimen for each individual patient, SGRM, and checkpoint inhibitor based on the disease or condition being treated.
[0213] The amount of active ingredient in a unit dose formulation can be varied or adjusted in the range of 0.1 mg to 6000 mg, more typically in the range of 1.0 mg to 3000 mg, and most typically in the range of 10 mg to 300 mg. Suitable dosages include about 1 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, or about 2000 mg, depending on the particular application and potency of the active ingredient. The composition can also contain other compatible therapeutic agents, if desired. Single or multiple administrations of the compositions can be administered based on the dosage and frequency as required and tolerated by the patient.
[0214] Compositions containing antibody checkpoint inhibitors should provide a sufficient amount of active ingredient, i.e., antibody checkpoint inhibitor, to effectively treat cancer when administered alone or in combination with a GRM (e.g., SGRM), e.g., to reduce ACC tumor burden or achieve other beneficial or desired clinical results related to cancer amelioration. That is, dosing regimens can vary, but can be routinely determined using standard methods. In some cases, the pharmaceutical composition includes a CIC, and it may be appropriate to administer the active ingredient in a daily dose of about 1 to 2,000 mg, preferably about 10 to about 1000 mg, and most preferably about 250 to 500 mg. This daily dose can be administered in one to four doses per day. Other dosing schedules include weekly administration and once every two days.
[0215] In some cases, the pharmaceutical composition contains a CIA, and the dosage (active ingredient dosage) ranges from about 0.0001 to 100 mg / kg of host body weight, more usually from 0.01 to 20 mg / kg. For example, the dosage can be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight, 10 mg / kg body weight, or within the range of 0.1 to 20 mg / kg. Exemplary treatment regimes entail administration once daily, once weekly, twice weekly, once every two weeks, once every three weeks, once every four weeks, once monthly, once every three months, or once every three to six months. In some cases, the treatment involves administering the CIA according to one of the above dosage regimes for a first period and another of the above dosage regimes for a second period. In some cases, after a period of cessation of treatment, the same or a different dosage regime is resumed. For example, a patient may be on a CIA regimen for two weeks, off for one week, on for two weeks, etc. Preferred CIA regimens of the invention include 0.1 mg / kg body weight, 0.3 mg / kg body weight, 2 mg / kg body weight, 3 mg / kg body weight, or 10 mg / kg by intravenous administration, with the antibody being given using one of the following dosing schedules: (i) six doses every four weeks, then every three months; (ii) every three weeks; (iii) one dose of 3 mg / kg body weight, then 1 mg / kg body weight every three weeks.
[0216] In some methods, two or more CIAs with different binding specificities are administered simultaneously, in which case the dosage of each antibody falls within the ranges described above. The CIAs are usually administered multiple times. The interval between each single administration can be, for example, weekly, monthly, every three months, or yearly. By measuring blood levels of antibody to the target antigen, the intervals can be irregular, as described above. In some methods, the dose is adjusted to achieve a plasma antibody concentration of about 1-1000 μg / ml, and in some methods, about 25-300 μg / ml.
[0217] The composition containing a GRM (e.g., SGRM) used in the combination therapy should provide an amount of active agent sufficient to effectively enhance the activity of the checkpoint inhibitor in treating cancer, e.g., an amount that, when combined with a therapeutic amount of an antibody checkpoint inhibitor, can reduce ACC tumor burden, restore T cell signaling pathways and natural killer (NK) cell signaling pathways, increase infiltration of T cells and NK cells into ACC tumors, reduce infiltration of neutrophils into ACC tumors, or provide greater relief of associated cancer symptoms, or achieve a more beneficial or desirable clinical outcome, compared to administration of the same therapeutic amount of the checkpoint inhibitor without the GRM (e.g., SGRM). In some cases, the composition provides an amount of GRM (e.g., SGRM) that sensitizes the ACC tumor to the checkpoint inhibitor, i.e., shows a reduction in tumor burden or other relevant clinical benefit that does not occur when the tumor is treated with the checkpoint inhibitor alone. For this reason, dosing regimens may vary depending on the route of administration and the type of cancer being treated, but can be routinely determined using standard methods. In some embodiments, a GRM (e.g., an SGRM) is administered monthly, twice monthly, three times monthly, every other week, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, six times weekly, every other day, once daily, twice daily, three times daily, or more frequently.
[0218] In some cases, daily oral dosages of pharmaceutical compositions containing a GRM (e.g., an SGRM) can be used in the methods disclosed herein and range from about 1 to about 2000 mg per day (mg / day). In some embodiments, the daily dosage is about 10 to 1000 mg / day, 50 to 500 mg / day, or 100 to 300 mg / day. Smaller dosages can be used, particularly when the agent is administered to an anatomically isolated location, such as the cerebrospinal fluid (CSF) space, into the bloodstream, into a body cavity, or into the lumen of an organ, as opposed to oral administration. Doses used for local administration can be significantly higher. Actual methods for preparing compositions for parenteral administration are known or apparent to those of skill in the art and are described in detail in publications such as Remington's, supra. See also Nieman, Receptor Mediated Antisteroid Action, Agarwal et al. (eds.), De Gruyter, New York (1987). In some embodiments, the SGRM is CORT125281. In some embodiments, the SGRM is CORT125134.
[0219] Pharmaceutical compositions containing a GRM (e.g., SGRM) or antibody checkpoint inhibitor of the invention can be formulated in an acceptable carrier, placed in an appropriate container, and labeled for treatment of a designated condition. In the case of administration of a GRM (e.g., SGRM) or checkpoint inhibitor, such labeling would include, for example, instructions regarding the amount, frequency, and method of administration.
[0220] Combination therapy The methods disclosed herein include combination therapy of administering both a GRM (e.g., an SGRM) and an antibody checkpoint inhibitor to a subject exhibiting an ACC tumor burden, which may be due to the presence of an antibody checkpoint inhibitor-sensitive cancer. In some embodiments, the combination therapy includes administration of an antibody checkpoint inhibitor and an SGRM, sequentially in any order during all or part of the treatment period. It is believed that combination therapy including administration of both a GRM (e.g., an SGRM) and an antibody checkpoint inhibitor to a subject exhibiting an ACC tumor burden is effective in reducing ACC tumor burden in a patient, restoring T cell signaling pathways and natural killer (NK) cell signaling pathways, increasing infiltration of T cells and NK cells into ACC tumors, reducing infiltration of neutrophils into ACC tumors, and providing other therapeutic benefits to the patient.
[0221] In some cases, the GRM (e.g., an SGRM) and the checkpoint inhibitor are administered according to the same dosing schedule or according to different dosing schedules. In some cases, the GRM (e.g., an SGRM) is administered according to a scheduled dosing schedule and the checkpoint inhibitor is administered intermittently. In some cases, the checkpoint inhibitor is administered according to a scheduled dosing schedule and the GRM (e.g., an SGRM) is administered intermittently. In some cases, both the GRM (e.g., an SGRM) and the checkpoint inhibitor are administered intermittently. In some embodiments, the GRM (e.g., an SGRM) is administered daily and the checkpoint inhibitor, e.g., an antibody checkpoint inhibitor, is administered weekly or biweekly.
[0222] In some cases, the GRM (e.g., SGRM) and checkpoint inhibitor are administered, sequentially or simultaneously, once or twice a month, three times a month, every other week, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, every other day, once a day, twice a day, three times a day, or more frequently, continuously for a period ranging from about 1 day to about 1 week, from about 2 weeks to about 4 weeks, from about 1 month to about 2 months, from about 2 months to about 4 months, from about 4 months to about 6 months, from about 6 months to about 8 months, from about 8 months to about 1 year, from about 1 year to about 2 years, or from about 2 years to about 4 years, or longer.
[0223] In some embodiments, the combination therapy comprises co-administration of a GRM (e.g., an SGRM) and an antibody checkpoint inhibitor. In some embodiments, co-administration of an antibody checkpoint inhibitor and a GRM (e.g., an SGRM) comprises administering the two agents simultaneously or approximately simultaneously (e.g., within about 1 minute, within about 5 minutes, within about 10 minutes, within about 15 minutes, within about 20 minutes, or within about 30 minutes of each other).
[0224] Various combinations of GRMs or SGRMs and antibody checkpoint inhibitors can be used to treat ACC patients with hypercortisolism. Such treatments can be effective in reducing ACC tumor burden in patients, restoring T cell signaling pathways and natural killer (NK) cell signaling pathways, increasing infiltration of T cells and NK cells into ACC tumors, decreasing infiltration of neutrophils into ACC tumors, and providing other therapeutic benefits to patients. "Combination therapy" or "in combination" is not intended to mean that the therapeutic agents must be administered simultaneously and / or formulated to be delivered together, although these delivery methods are within the scope of the present disclosure. The GRMs or SGRMs and antibody checkpoint inhibitors can be administered according to the same dosing schedule or according to different dosing schedules. In some embodiments, the GRMs or SGRMs and antibody checkpoint inhibitors are administered sequentially in any order during all or part of the treatment period. In some embodiments, the GRM or SGRM and the antibody checkpoint inhibitor are administered simultaneously or approximately simultaneously (e.g., within about 1 minute, within about 5 minutes, within about 10 minutes, within about 15 minutes, within about 20 minutes, or within about 30 minutes of each other). A non-limiting example of a combination therapy, for example, by administration of a GRM or SGRM and an antibody checkpoint inhibitor, is as follows, where the GRM or SGRM is "A" and the antibody checkpoint inhibitor given as part of a chemo therapy regime is "B".
[0225] A / B / AB / A / BB / B / AA / A / BA / B / BB / A / AA / B / B / BB / A / B / B
[0226] B / B / B / AB / B / A / BA / A / B / BA / B / A / BA / B / B / AB / B / A / A
[0227] B / A / B / AB / A / A / BA / A / A / BB / A / A / AA / B / A / AA / A / B / A
[0228] Administration of the therapeutic compound or agent to the patient will follow standard protocols for the administration of such compounds, taking into account the toxicity, if any, of the treatment. Surgical interventions may also be applied in combination with the described treatments.
[0229] The method may be combined with other means of treatment, such as surgery, radiation, targeted therapy, immunotherapy, the use of growth factor inhibitors, or anti-angiogenic factors.
[0230] period The duration of treatment with a GRM (e.g., SGRM) and antibody checkpoint inhibitor to reduce tumor burden, restore T cell and natural killer (NK) cell signaling pathways, increase T and NK cell infiltration into ACC tumors, decrease neutrophil infiltration into ACC tumors, and provide other therapeutic benefits to the patient may vary depending on the severity of the condition in the subject and the subject's response to the combination therapy. In some embodiments, the GRM (e.g., SGRM) and / or checkpoint inhibitor may be administered for a period of about 1 week to 104 weeks (2 years), more typically for a period of about 6 weeks to 80 weeks, and most typically for a period of about 9 weeks to 60 weeks. Suitable administration periods include 5 to 9 weeks, 5 to 16 weeks, 9 to 16 weeks, 16 to 24 weeks, 16 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 weeks, 32 to 52 weeks, 48 to 52 weeks, 48 to 64 weeks, 52 to 64 weeks, 52 to 72 weeks, 64 to 72 weeks, 64 to 80 weeks, 72 to 80 weeks, 72 to 88 weeks, 80 to 88 weeks, 80 to 96 weeks, 88 to 96 weeks, and 96 to 104 weeks. Suitable administration periods also include 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 24 weeks, 25 weeks, 30 weeks, 32 weeks, 35 weeks, 40 weeks, 45 weeks, 48 weeks, 50 weeks, 52 weeks, 55 weeks, 60 weeks, 64 weeks, 65 weeks, 68 weeks, 70 weeks, 72 weeks, 75 weeks, 80 weeks, 85 weeks, 88 weeks, 90 weeks, 95 weeks, 96 weeks, 100 weeks, and 104 weeks. Typically, administration of the SGRM and / or antibody checkpoint inhibitor should be continued until the desired clinical benefit is confirmed, and may be continued after such benefit is confirmed, such as to maintain or further enhance such benefit. Treatment with a GRM (e.g., SGRM) and antibody checkpoint inhibitor in the present invention may continue for as long as two years, or even longer, in some embodiments, the duration of GRM (e.g., SGRM) administration is the same as the duration of checkpoint inhibitor administration.In some embodiments, the duration of administration of the SGRM is shorter or longer than the duration of administration of the checkpoint inhibitor.
[0231] In some embodiments, administration of the GRM (e.g., SGRM) or antibody checkpoint inhibitor is not continuous, but can be followed by one or more drug-free periods followed by one or more drug-resumption periods. Suitable drug-free periods include 5 to 9 weeks, 5 to 16 weeks, 9 to 16 weeks, 16 to 24 weeks, 16 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 weeks, 32 to 52 weeks, 48 to 52 weeks, 48 to 64 weeks, 52 to 64 weeks, 52 to 72 weeks, 64 to 72 weeks, 64 to 80 weeks, 72 to 80 weeks, 72 to 88 weeks, 80 to 88 weeks, 80 to 96 weeks, 88 to 96 weeks, and 96 to 100 weeks. Suitable drug holiday periods include 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 24 weeks, 25 weeks, 30 weeks, 32 weeks, 35 weeks, 40 weeks, 45 weeks, 48 weeks, 50 weeks, 52 weeks, 55 weeks, 60 weeks, 64 weeks, 65 weeks, 68 weeks, 70 weeks, 72 weeks, 75 weeks, 80 weeks, 85 weeks, 88 weeks, 90 weeks, 95 weeks, 96 weeks, and 100 weeks.
[0232] (Evaluating improvements in the treatment of ACC in patients with hypercortisolism, including reduction in tumor burden) The combination therapy disclosed herein is believed to be effective in treating patients with hypercortisolism and ACC tumors; in some embodiments, such treatment may be effective in reducing tumor burden in patients, restoring T cell signaling pathways and natural killer (NK) cell signaling pathways, increasing infiltration of T cells and NK cells into ACC tumors, reducing infiltration of neutrophils into ACC tumors, and providing other therapeutic benefits to patients. Methods for measuring these responses are well known to those skilled in the art of cancer treatment. For example, methods for measuring tumor burden are described in the Response Evaluation Criteria in Solid Tumors ("RECIST") criteria, available at http: / / ctep.cancer.gov / protocolDevelopment / docs / recist_guideline.pdf.
[0233] In one approach, tumor burden is measured by quantifying the expression of tumor-specific gene markers. This approach is particularly useful for metastatic tumors or tumors that are not easily measured (e.g., bone marrow cancer). Tumor-specific gene markers are molecules, such as proteins, that are unique to cancer cells or that are more abundant in cancer cells than in non-cancerous cells. See, for example, WO2006104474. Non-limiting examples of tumor-specific gene markers include alpha-fetoprotein (AFP) for liver cancer, beta-2-microglobulin (B2M) for multiple myeloma, beta-human chorionic gonadotropin (beta-hCG) for choriocarcinoma and germ cell tumors, CA19-9 for pancreatic, gallbladder, bile duct, and gastric cancers, CA-125 and HE4 for ovarian cancer, carcinoembryonic antigen (CEA) for colorectal cancer, chromogranin A (CgA) for neuroendocrine tumors, fibrin / fibrinogen for bladder cancer, prostate-specific antigen (PSA) for prostate cancer, and thyroglobulin for thyroid cancer. See http: / / www.cancer.gov / about-cancer / diagnosis-staging / diagnosis / tumor-markers-fact-sheet.
[0234] Methods for measuring the expression level of tumor-specific gene markers are well known. In some embodiments, mRNA of the gene marker is isolated from blood samples or tumor tissues, and real-time reverse transcriptase polymerase chain reaction (RT-PCR) is performed to quantify the expression of the gene marker. In some embodiments, Western blot or immunohistochemistry analysis is performed to evaluate the protein expression of the tumor-specific gene marker. Typically, the level of the tumor-specific gene marker is measured in multiple samples taken over the course of the combination therapy of the present invention, and a decrease in the level correlates with a decrease in tumor burden.
[0235] In another approach, the reduction in tumor burden by the combination therapy disclosed herein is indicated by a reduction in tumor size or a reduction in the amount of cancer in the body. Measurement of tumor size is typically achieved by imaging-based methods. For example, computed tomography (CT) can provide accurate and reliable anatomical information on tumor shrinkage or growth, as well as disease progression, by identifying the growth of existing lesions or the occurrence of new lesions or tumor metastases. The restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and reduced infiltration of neutrophils in ACC tumors in patients can be measured by imaging-based methods or other suitable means.
[0236] In another approach, the reduction in tumor burden, restoration of T cell and natural killer (NK) cell signaling pathways, increased infiltration of T and NK cells into ACC tumors, and decreased infiltration of neutrophils in ACC tumors can be assessed in patients by functional and metabolic imaging techniques. These techniques allow earlier assessment of treatment response by observing changes in perfusion, oxygenation, and metabolism. For example, 18F-FDG PET uses radiolabeled glucose analogue molecules to assess tissue metabolism. Tumors typically have elevated glucose uptake, and changes in values corresponding to decreased tumor tissue metabolism indicate decreased tumor burden. A similar imaging technique is disclosed in Kang et al., Korean J.Radiol., (2012), Vol. 13(No. 4), pp. 371-390.
[0237] Patients receiving the combination therapy disclosed herein may show varying degrees of tumor burden reduction, and may show varying restoration of T cell and natural killer (NK) cell signaling pathways, increased infiltration of T cells and NK cells into ACC tumors, and decreased infiltration of neutrophils in ACC tumors. In some cases, patients may show a complete response (CR), also referred to as "no evidence of disease (NED)". CR means that tests, examinations, and scans show that all detectable tumors have disappeared. In some cases, patients receiving the combination therapy disclosed herein may show a partial response (PR), roughly corresponding to at least a 50% reduction in total tumor volume, but still with some evidence of residual disease. In some cases, the residual disease in a deep partial response may actually be dead tumor or scar, so that a small number of patients classified as PR patients may actually be CR patients. Also, many patients who show shrinkage during treatment may show further shrinkage with continued treatment and achieve CR. In some cases, patients receiving combination therapy may have a minor response (MR), which roughly means a small shrinkage of more than 25% of the total tumor volume but less than the 50% that would result in a PR. In some cases, patients receiving combination therapy may have stable disease (SD), which means the tumor remains roughly the same size but may show either a small amount of growth (typically less than 20% or 25%) or a small amount of shrinkage (anything less than a PR, as long as a minor response occurs; in that case, SD is typically defined as less than 25%).
[0238] In addition to reducing ACC tumor burden, restoring T cell signaling pathways and natural killer (NK) cell signaling pathways, increasing infiltration of T cells and NK cells into ACC tumors, and reducing infiltration of neutrophils into ACC tumors, desired beneficial results or desired clinical outcomes from the combination therapy may also include, for example, reducing (i.e., slowing and / or stopping to some extent) infiltration of cancer cells into peripheral organs; inhibiting (i.e., slowing and / or stopping to some extent) tumor metastasis; increasing the response rate (RR); prolonging the duration of response; alleviating to some extent one or more symptoms associated with the cancer; reducing the dosage of other therapeutic agents required to treat the disease; delaying the progression of the disease; and / or prolonging the survival and / or improving the quality of life of the patient. Methods for assessing these effects are well known and / or disclosed, such as those described above at http: / / cancerguide.org / endpoints.html and RECIST guidelines. EXAMPLES
[0239] The following examples are offered by way of illustration only, and not by way of limitation. Those of skill in the art will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially similar results.
[0240] Example 1. HepG2 Tyrosine Aminotransferase (TAT) Assay The following protocol describes an assay to measure induction of TAT by dexamethasone in HepG2 cells (human hepatoma cell line; ECACC, UK). HepG2 cells are cultured in MEME medium supplemented with 10% (v / v) fetal bovine serum; 2 mM L-glutamine and 1% (v / v) NEAA at 37° C., 5% / 95% (v / v) CO2 / air. The HepG2 cells are then counted and cultured at 0.125×10 in phenol red-free RPMI 1640, 10% (v / v) charcoal-stripped FBS, 2 mM L-glutamine. 6The density of cells / ml is adjusted and seeded into 96-well sterile tissue culture microtiter plates at 25,000 cells / well in 200 μl and incubated at 37° C., 5% CO 2 for 24 hours.
[0241] Growth medium is then removed and replaced with assay medium {RPMI 1640 without phenol red, 2 mM L-glutamine + 10 μM forskolin}. Test compounds are then screened against a 100 nM dexamethasone challenge. Compounds are then serially half-log diluted from a 10 mM stock in 100% (v / v) dimethyl sulfoxide. An 8-point half-log dilution curve is then generated, followed by a 1:100 dilution in assay medium to give a final assay compound concentration of 10×, resulting in final assay compound concentrations that are in the range of 10-0.003 μM in 0.1% (v / v) dimethyl sulfoxide.
[0242] Test compounds are pre-incubated in microtiter plates at 37° C., 5 / 95 (v / v) CO 2 / air for 30 min before addition of 100 nM dexamethasone, followed by 20 h to allow optimal TAT induction.
[0243] HepG2 cells are then lysed with 30 μl of cell lysis buffer containing a protease inhibitor cocktail for 15 minutes at 4° C. Then 155 μl of substrate mixture containing 5.4 mM tyrosine sodium salt, 10.8 mM alpha-ketoglutarate and 0.06 mM pyridoxal 5′ phosphate in 0.1 M potassium phosphate buffer (pH 7.4) can be added. After 2 hours of incubation at 37° C., the reaction can be terminated by the addition of 15 μl of 10 M aqueous potassium hydroxide solution, and the plate can be incubated for another 30 minutes at 37° C. TAT activity product can be measured by absorbance at λ340 nm.
[0244] I C 50Values can be calculated by plotting % inhibition (normalized to 100 nM dexamethasone TAT stimulation) versus compound concentration and fitting this data to a four parameter logistic equation: IC 50 Values can be converted to Ki (equilibrium dissociation constant) using the Cheng-Prusoff equation, assuming that the antagonist is a competitive inhibitor with respect to dexamethasone.
[0245] Example 2: Gene Expression in ACC Tumor Patients with Cortisol Excess Methods: GC status, mRNA expression, DNA mutations, and DNA methylation data from separate adrenalectomies (n=71) were accessed from The Cancer Genome Atlas (TCGA) (accessible at cancer.gov at the URL: about-nci / organization / ccg / research / srtuctural-genomics / tcga). To analyze the abundance of immune cell types, xCell was applied to the mRNA data. Random forests were used to extract gene signatures (Aran, Dvir, Zicheng Hu, and Atul J. Butte. "xCell: digitally portraying the tissue cellular heterogeneity landscape." Genome biology, vol. 18, no. 1 (2017): p. 220). Gene analysis may also be performed from cBioPortal (accessible at cbioportal.org).
[0246] Results: The expression of 858 genes was significantly different between GC-ACC and GC+ACC cases. KEGG pathway analysis showed that gene expression of 7 pathways involved in steroid synthesis and secretion was elevated in GC+ cases. Nineteen pathways showed decreased expression, most of which were related to natural killer cells, T cells, and immune activity. Hypomethylation was mainly observed in the steroid synthesis pathway. Tumor-infiltrating CD4 +Memory T cells (P = .003), CD8 + Memory T cells (P<.001) and NKT cells (P=.014) were depleted, whereas tumor-associated neutrophils were enriched (P<.001).GC+ cases were identified as having a higher tumor mutation burden (TMB) (P=.029).
[0247] GC+ACC tumors showed certain differences in immune processes compared to ACC tumors without systemic cortisol excess. Specifically, genes involved in natural killer (NK)-mediated cytotoxicity, T H 17 Genes involved in cell differentiation, genes involved in T cell receptor signaling, T H Genes involved in 1 / 2 differentiation, as well as antigen processing and presentation, were downregulated in GC+ACC tumors (Figure 1).
[0248] Furthermore, the presence or absence of certain immune cells differed between ACC tumors with and without cortisol excess: CD4+ naive T cells, CD4+ memory T cells, CD8+ T cells, CD8+ central memory T cells, and natural killer T cells (NKT) were less abundant in GC+ cases (Figure 2). In contrast, tumor-associated neutrophils (TAN) were more abundant in GC+ACC.
[0249] The abundance of immune cells and immune-related transcripts was lower in GC+ACC. The higher TMB in GC+ tumors may be related to increased neoantigen resistance. These findings suggest that GR antagonism may promote tumor immune responses in ACC or other malignancies with elevated GC activity by reversing the immunosuppressive effects of endogenous GCs.
[0250] Conclusion: Clinical responses to antibody checkpoint inhibitors are immune system dependent. Specifically, T cell function and antigen presentation are important for the clinical efficacy of antibody checkpoint inhibitors. Furthermore, immune cell infiltration is associated with the clinical efficacy of antibody checkpoint inhibitors. Tumors with low T cell infiltration or high neutrophil infiltration tend to respond poorly to antibody checkpoint inhibitors. In other words, reversing the effects of GC+ with GRMs (e.g., SGRMs) may improve the response to antibody checkpoint inhibitors. Thus, the combined administration of GRMs, such as SGRMs, and antibody checkpoint inhibitors may be effective in reducing tumor burden, restoring T cell and natural killer (NK) cell signaling pathways, increasing infiltration of T cells and NK cells into ACC tumors, and decreasing infiltration of neutrophils into ACC tumors in ACC patients with hypercortisolism.
[0251] Example 3: Gene Expression in ACC Tumor Patients with Cortisol Excess Methods: Data on GC status (based on clinical signs and symptoms or biochemical findings), mRNA expression, DNA mutations, and DNA methylation from separate adrenalectomies (n=71) were accessed from TCGA (www.cancer.gov / tcga). Two sarcomatoid cases were excluded from the analysis. 394,036 methylation probes were analyzed and data were normalized using beta-mixture quantile normalization (BMIQ). To analyze immune cell type abundance, xCell was applied to the above mRNA data (Aran et al., Genome Biol. 18(1):220 (2017)). Each tumor case was scored using a previously published signature of GR activity (West et al., 24(14):3433-3446 (2018)). Random forests were used to extract gene signatures predictive of GC+ tumors. Signature genes were identified by bootstrapping a random forest on a random subset containing 80% of the data and comparing the average bootstrapped gene importance to a threshold. The threshold was calculated by applying the same procedure to a random forest that predicted randomized labels instead of the true GC+ / - labels to simulate signal paucity. The 99.9th quantile of gene importance was chosen as the threshold.
[0252] Results: Tumor glucocorticoid status was used to classify adrenocortical carcinomas (Figure 3A). Using TCGA mRNA data, genes that were significantly different (>2-fold change and adjusted P ≤ 0.05) with respect to common hormone and GC status were identified. The presence or absence of GC excess (GC+ / -) was identified to affect the largest number of genes (858 genes, Figure 3A comparison 1, illustrated in Figure 3B). The presence or absence of any hormone (H+ / -) was significantly different in 439 genes (comparison 2). (H+ represents the presence of hormones, H- represents the absence of hormones (e.g., no GC, no androgen, no estrogen, no progesterone, etc.) There were no significant differences between H- tumors and tumors expressing only hormones other than GC (NGC+, comparison 3). Comparison of NGC+ with GC+ revealed significant differences in 185 genes (comparison 4). Pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) confirmed that gene expression in several steroid synthesis pathways was elevated and expression in numerous immune-related pathways was decreased in GC+ cases (Figure 1).
[0253] As mentioned in Example 2 above, Figure 2 shows the abundance of certain immune cell types in ACC tumors. GC+ cases had low lymphocyte abundance (left) and high mesenchymal stem cell and neutrophil abundance (right). GC+ACC tumors had low lymphocyte abundance, high myeloid stem cell and mesenchymal stem cell abundance, and high tumor mutation burden. xCell analysis showed low abundance of T cells (P<.005) and natural killer T cells (NKT cells, P=.014) in GC+ cases compared to GC- (Figure 2, left). Meanwhile, mesenchymal stem cells and neutrophils were more abundant in GC+ cases (P<.001, Figure 2, right). The tumor mutation burden was also confirmed to be higher in GC+ cases (P=.029, Figure 7).
[0254] As shown in Figure 3B, the expression of 858 genes was found to be significantly affected by GC excess. Genes that were highly expressed in GC+ cases (P ≤ .05 and >2-fold change in expression compared to GC-) are shown in the top right. Genes that were less expressed in GC+ cases are shown in the top left.
[0255] GC overload is associated with hypomethylation of steroidogenic genes (Figure 4). In GC+ACC cases, a large number of genes were significantly hypomethylated (Figure 4, top left), whereas only a few genes were hypermethylated (Figure 4, top right). In GC+ tumors, there were more genes that were significantly hypomethylated (P ≤ 0.05, Δβ < -0.2) than hypermethylated (P ≤ 0.05, Δβ > 0.2) (Figure 4). β values represent the percentage of methylation in a gene. The differential methylation may explain the upregulation of steroidogenic pathways, but not the downregulation of immune pathways. The hypomethylated genes were mainly associated with aldosterone, GC, and bile synthesis / secretion pathways, which are upregulated in GC+ACC (Figure 1). In contrast, immune pathways with downregulated gene expression confirmed by mRNA analysis were not enriched in either the hypomethylated or hypermethylated sets.
[0256] As shown in Figures 5 and 6, suppression of immune genes is associated with GC production. Unsupervised clustering of normalized gene expression for the T cell receptor signaling KEGG pathway and the natural killer cell-mediated cytotoxicity KEGG pathway showed lower gene expression in GC+ cases (Figure 5). Conversely, when GC+ and GC- were clustered separately, GC+ cases showed a trend toward lower expression of these two immune-related pathways (Figure 6).
[0257] Figure 5 shows unsupervised clustering of normalized gene expression for two KEGG pathways. Pathways shown include the T cell receptor signaling pathway and the natural killer cell-mediated cytotoxicity pathway. The top two columns show the GC and general hormone status of each tumor (black: GC+ / H+, white: GC- / H-), and the blue / red shades (shown in greyscale) show the normalized gene expression of each tumor, with darker blue corresponding to lower expression. When clustered by gene expression, GC+ cases appear on the right side of the figure, with many genes showing lower expression.
[0258] Figure 6. Supervised clustering of normalized gene expression for the two KEGG pathways shown in Figure 5. In GC+ cases (clustered on the right), low gene expression predominates in these pathways (dark blue).
[0259] Figure 7. Elevated tumor mutation burden in GC+ACC. More missense and nonsense mutations were identified in GC+ cases compared to GC- cases. (A case is an individual patient's tumor. "Mutations per case" is the total number of mutations identified in a tumor.)
[0260] Figure 8. GR activity scores in different tumor types and ACC subsets. ACC showed higher GR-driven gene activity compared to other tumors, independent of hormone status (see inset). GR activity is higher in ACC and independent of hormone status. Tumor scoring using a previously published GR-driven gene signature (West et al., 2018), determined from 74 GR activation-associated genes, confirmed that GR activity was higher in ACC compared to other tumor types in The Cancer Genome Atlas (TCGA; Figure 8). There was no difference between ACC cases with different hormone or GC status (Figure 8 inset).
[0261] Figure 9. Gene signatures can predict GC+-like tumor cases. Figure 9 shows the derivation of a gene signature that distinguishes between GC+ACC and GC-ACC cases using random forest analysis. NLRP1 and ZNF683 (highlighted) were identified as significant signature components. Only signature genes above a threshold of 0.0028 are shown. A model was derived using random forests that distinguishes between GC+ACC and GC-ACC cases with a ROC AUC=0.87±0.09 (Figure 9). A sensor component of the inflammasome (NLRP1) and a mediator of NK activation by IL-15 (ZNF683) were identified as key parts of this signature (inset of Figure 9).
[0262] We then applied the gene signature to other tumor types in TCGA, identifying tumor types with GC+-like transcriptional profiles, as shown in Figures 10A and 10B. Figure 10A shows the application of the ACC gene signature to TCGA tumors. Based on the known distribution of GC+ and GC- cases in ACC, we derived a cutoff score of 0.75 to distinguish GC+ and GC- tumors (horizontal line in Figure 10A). According to this score, uveal melanoma (UVM) and cutaneous melanoma (SKCM) are likely to have the highest frequency of cases similar to GC+ACC (Figure 10B). Figure 10B shows the predicted frequency of tumor cases similar to GC+ACC. Uveal melanoma (UVM) and cutaneous melanoma (SKCM) are predicted to have the highest frequency of tumors similar to GC+ACC.
[0263] In ACC, glucocorticoid excess (GC+) affects many more genes than other hormones. In GC+ACC, expression of steroidogenic genes was elevated and immune-related genes were suppressed. Normal adrenal cells express steroidogenic genes but not immunosuppressive genes. Steroidogenic genes were hypomethylated in GC+ cases, but no differences in immune gene methylation were identified between GC+ and GC- cases. Furthermore, fewer infiltrating immune cells (T cells and NKT cells) were found in GC+ cases compared with GC- cases, suggesting that immune effects are due to changes in immune cell infiltration rather than changes in transcription. Tumor gene mutation burden was higher in GC+ACC cases, which may be due to immune suppression or immune cell elimination, which may be related to the higher non-self antigen tolerance identified in GC+ cases. Published GR activity scores did not differ between GC+ and GC- cases, which may be due to the fact that GC concentrations are locally higher in the adrenal gland, regardless of systemic GC levels. On the other hand, immune infiltration within ACC tumors can be negatively affected by lymph node exposure to elevated GC activity. A newly derived gene signature predicts that uveal and cutaneous melanomas have the highest frequency of GC+-like tumors. Reduced abundance of immune cells and immune-related transcripts was identified in GC+ACC, providing insight into the mechanism by which GCs may limit responses to immune checkpoint inhibitor (ICI) therapy. GR antagonism increases immune-related transcripts and immune cell infiltration, which may promote tumor immune responses in malignancies such as GC+ACC with elevated GC activity.
[0264] Example 4. Effects of Cortisol and Relacorilant on Natural Killer Cell Function In Vitro Given the striking differences in natural killer (NK) cells between GC+ACC and GC-ACC, the effect of cortisol on human NK cells was evaluated in vitro. Cortisol suppressed (and relacorilant restored) NK cell activation, proliferation, and direct tumor cell killing. The abundance of immune cells such as NK cells was decreased in GC+ACC, providing clues as to the mechanism by which GCs may limit the response to ICI therapy. GR antagonism may increase the abundance and function of immune cells such as NK cells in tumors, thus promoting tumor immune responses in malignancies such as GC+ACC, which have elevated GC activity. This hypothesis will be tested in a phase 1 clinical trial of relacorilant plus ICI.
[0265] Effects of cortisol and relacorilant on NK cell function in vitro. Given the prominent repression of NK-related genes in GC+ cases, we evaluated the direct impact of GR modulation of human NK cells. NK cells were isolated from healthy donors and stimulated with IL-2. Activation (abundance of CD25+CD69+ cells) was increased by stimulation, suppressed by cortisol, and restored by leucorilant (Mann-Whitney p=0.0039) (Figure 11A). NK cell proliferation was also increased by stimulation, suppressed by cortisol, and restored by leucorilant (Mann-Whitney p=0.0099) (Figure 11B). Cytokine secretion (both transcripts and secreted proteins) was also increased by stimulation, suppressed by cortisol, and restored by leucorilant (Figures 12A-D). Genes significantly induced by stimulation, suppressed by cortisol, and restored by leucorilant included key NK activation genes, including the IL2 receptor and activator LAG3 (Figure 12D). These data experimentally confirm the observed effects of GCs on NK cell populations in ACC tumors.
[0266] Activation, proliferation, and cytokine secretion all indicate cortisol- and lelacorilant-mediated functional changes in NK cells. To determine whether these functional changes also affect target cell killing, NK cells were incubated with K562 tumor cells. At various NK cell:tumor cell ratios, cortisol inhibited tumor cell killing, and lelacorilant restored it (Figure 13A). When lelacorilant was added to NK cells at a 5:1 ratio, NK cell tumor killing was significantly improved (Mann-Whitney p=0.004) (Figure 13B). Thus, glucocorticoids inhibit tumor cell killing by human NK cells in vitro.
[0267] Cortisol is a potent transcriptional regulator and mediator of immune cell function. The effects of systemic cortisol activity are challenging to assess, as circadian and ultradiurnal variations in cortisol limit the interpretability of a single cortisol assessment. Multi-omics data from ACC provide a unique scenario in which rich multi-omics data are paired with clinical assessment of cortisol excess. We investigated this exaggerated cortisol physiology to improve our understanding of ACC and further glean insights into possible underlying manifestations of cortisol activity in other tumor types.
[0268] Significant differences in 858 genes were identified between ACC cases with and without GC excess. Other comparisons, such as with and without any steroid hormone, showed few significantly different genes. Genes involved in steroid synthesis were not surprisingly overexpressed in GC excess cases. Promoter hypomethylation was observed in steroid synthesis genes. On the other hand, the reduced expression of immune genes in GC+ cases may be the result of poor infiltration of immune cells into GC+ tumors. Assessment of GR activity (through a previously published gene signature; see West et al., Clin Cancer Res, 2018, 24(14):3433-3446) suggested that GR activity in tumors was similar in ACC cases with and without GC excess. This may be caused by high cortisol levels in the adrenal glands, independent of systemic cortisol levels. Thus, the difference in immune infiltration may be due to systemic GC action, including effects on primary and secondary lymphoid organs throughout the body. Because high GCs can increase tolerance to neoantigens, the effect of GCs on lymphoid organs may also be related to the increased TMB observed in GC+ACC cases.
[0269] Using a comparison between GC+ and GC- cases, we found a gene signature that could distinguish between the two cases. This gene signature could be useful in future efforts to diagnose GC excess from tumor biopsies or tumor resections. When non-ACC tumors were scored for this signature, uveal and cutaneous melanomas showed the most cases (although still rare) that resembled the transcriptional signature of GC+ACC. This supports previous reports of local cortisol production in the skin (see Vekulic et al., and Tissue Injury., J Biological Chemistry, 2011, 286(12), pp10265-10275). Such tumors would be reasonable options for evaluating the immune effects of GR antagonism outside of ACC.
[0270] In the multiomics data of GC+ACC, suppression of NK cells was prominent. NK activation genes were significantly underexpressed in GC+ cases, and the NK activation gene ZNF683 was a particularly important gene in distinguishing GC+ from GC- cases. Functional studies using human NK cells, cortisol, and the GR modulator relacorilant confirmed that GR is a key regulator of NK function. Cortisol suppressed NK proliferation, upregulation of cell surface markers of activation, tumor cell killing, IFNγ secretion, and IFNγ transcription. Cortisol also suppressed secretion of other effector cytokines and expression of the IL-2 receptor (il2ra). These findings corroborate the reduction in NK activation genes identified in GC+ACC. Cortisol suppressed, and relacorilant promoted, expression of LAG3 (CD223, lag3) and 4-1BB (CD137, tnfrsf9), both targets of experimental agonists aimed at improving antitumor immune responses. Expression of chemokine ligand 3-like 1 (ccl3l1), a lymphocyte-attracting chemokine, was also suppressed by cortisol in stimulated NK cells, which may also explain the reduced T cell infiltration into GC+ACC. Reduced abundance of immune-related transcripts was identified in GC+ACC, providing insight into mechanisms that may limit response to ICI therapy.
[0271] Adrenal cancer is a serious disease where patients face challenges in both tumor and hormone management. ACC patients with cortisol excess suffer from Cushing's syndrome, a condition with systemic cortisol excess of adrenal, pituitary, or ectopic origin. Cushing's syndrome itself can lead to death in these patients through vascular events, cardiovascular events, or infection (see Yaneva M. et al., European J Endocrinology, 2013, vol. 169, pp. 621-627). The GR modulator Korylm™ (mifepristone) has been approved for the treatment of symptoms of cortisol excess. Going one step further, these data suggest that selective GR modulation by relacorilant may alleviate the immunosuppression caused by systemic cortisol. That is, selective GR antagonism may enhance the antitumor activity of other immune modulators, such as immune checkpoint inhibitors and more experimental NK-targeted agents, while reducing the potentially dangerous sequelae of cortisol excess. This hypothesis is being directly addressed in an ongoing Phase I study of relacorilant plus pembrolizumab in patients with ACC who exhibit GC excess.
[0272] The effect of GC excess on NK cells is particularly striking, and when cortisol action on NK cells was directly evaluated in vitro, a strong and broad inhibitory activity was confirmed. Furthermore, Relacorilant was able to reverse the effect of cortisol and restore NK cell activation, proliferation, and target cell killing. Thus, the treatment of adrenocortical carcinoma patients with cortisol excess (GC+ACC) by combined administration of a GR modulator such as Relacorilant and an immune checkpoint inhibitor (ICI) is believed to provide an effective and improved treatment compared to treatment with ICI alone.
[0273] All patents, patent publications, publications, and patent applications recited in this specification are hereby incorporated by reference in their entirety into this specification, as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. In addition, although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those skilled in the art in light of the teachings of the present invention that certain changes and modifications can be made without departing from the spirit or scope of the appended claims.
Claims
1. 1. A method of treating a subject having an adrenocortical carcinoma tumor and having cortisol excess, said method comprising: To identify patients who a) have an adrenal cortical tumor and b) have glucocorticoid excess; administering to said identified patient a combination treatment comprising administering 1) a selective glucocorticoid receptor modulator (SGRM) and 2) an antibody checkpoint inhibitor; thereby achieving a better treatment outcome from said identified patients than would have been achieved by treatment with an antibody checkpoint inhibitor alone; Including, The treatment outcome is selected from: a) a reduction in ACC tumor burden; b) restoration of T cell signaling pathways and natural killer (NK) cell signaling pathways; c) increased infiltration of T cells and NK cells into the ACC tumor; and d) reduced infiltration of neutrophils into the ACC tumor in the patient.
2. 2. The method of claim 1, wherein the antibody checkpoint inhibitor is selected from an antibody effective against PD-1, an antibody effective against CTLA-4, an antibody effective against PD-L1, and an antibody effective against PD-L2.
3. The method of claim 2, wherein the checkpoint inhibitor is an antibody effective against PD-1.
4. The method of claim 2, wherein the checkpoint inhibitor is an antibody effective against CTLA-4.
5. The method of claim 2, wherein the checkpoint inhibitor is an antibody effective against PD-L1.
6. The method of claim 2, wherein the checkpoint inhibitor is an antibody effective against PD-L2.
7. 7. The method of any one of claims 1 to 6, further comprising administering a chemotherapeutic agent selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducers, antimetabolites, mitotic inhibitors, and combinations thereof.
8. 8. The method of claim 7, wherein the chemotherapeutic agent is a taxane.
9. 9. The method of claim 8, wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin, and capecitabine.
10. The method of any one of claims 1 to 9, wherein the SGRM is a heteroaryl-ketone fused azadecalin compound having the formula: [Formula 1] During the ceremony, R 1 is a heteroaryl ring having 5 to 6 ring members and having 1 to 4 heteroatoms each independently selected from the group consisting of N, O, and S, each heteroaryl ring being independently selected from R 1a may be substituted with 1 to 4 groups selected from R 1a are each independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, CN, N-oxide, C 3-8 Cycloalkyl, and C 3-8 heterocycloalkyl; Ring J is selected from the group consisting of cycloalkyl rings, heterocycloalkyl rings, aryl rings, and heteroaryl rings, wherein said heterocycloalkyl rings and heteroaryl rings have 5 to 6 ring members and 1 to 4 heteroatoms each independently selected from the group consisting of N, O, and S; R 2 are each independently hydrogen, C 1-6 Alkyl, halogen, C 1 6 Haloalkyl, C 1 6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl-C 1-6 Alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , S.R. 2a , S(O)R 2a , S(O) 2 R 2a , C 3-8 Cycloalkyl, and C 3-8 heterocycloalkyl, wherein the heterocycloalkyl group is selected from the group consisting of 1 to 4 R 2c may be substituted with a group; Alternatively, two R attached to the same carbon 2 groups combine to form an oxo group (=O); Or, two R 2 The groups combine to form a heterocycloalkyl ring having 5 to 6 ring members and 1 to 3 heteroatoms each independently selected from the group consisting of N, O, and S, where the heterocycloalkyl ring is comprised of 1 to 3 R 2d may be substituted with a group; R 2a and R 2b are each independently hydrogen and C 1-6 selected from the group consisting of alkyl; R 2c are each independently hydrogen, halogen, hydroxy, C 1-6 Alkoxy, C 1-6 Haloalkoxy, CN, and NR 2a R 2b selected from the group consisting of: R 2d are each independently hydrogen and C 1-6 alkyl; or two R attached to the same ring atom; 2d the groups combine to form (=O); R 3 Each has 1 to 4 R 3a phenyl and pyridyl, each of which may be substituted with an alkyl group; R 3a are each independently hydrogen, halogen, or C 1-6 haloalkyl; The subscript n is an integer from 0 to 3.
11. 11. The method of claim 10, wherein the compound comprising a heteroaryl-ketone fused azadecalin is a relacorilant having the formula: [chemical 2]
12. The method of any one of claims 1 to 9, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PD-1.
13. The method of any one of claims 1 to 9, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against CTLA-4.
14. The method of any one of claims 1 to 9, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PD-L1.
15. The method of any one of claims 1 to 9, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PDL-2.
16. The method of any one of claims 1 to 9, wherein the SGRM is a fused azadecalin compound having the formula: [C3] During the ceremony, L 1 and L 2 is a member independently selected from a bond and unsubstituted alkylene; R 1is unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, -OR 1A , N.R. 1C R 1D , -C(O)NR 1C R 1D and -C(O)OR 1A where R is an element selected from 1A is a member selected from hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl; R 1C and R 1D are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl, which may be joined together to form an unsubstituted ring together with the nitrogen to which they are attached, said ring optionally including an additional ring nitrogen; R 2 has the formula: [C4] During the ceremony, R 2G is hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, -CN, and -CF 3 An element selected from: J is phenyl; t is an integer from 0 to 5; X is -S(O 2 )—and R 5 is 1 to 5 R 5A phenyl optionally substituted with a group; R 5A is hydrogen, halogen, -OR 5A1 , S(O 2 ) N.R. 5A2 R 5A3 , —CN, and unsubstituted alkyl; R 5A1 is a member selected from hydrogen and unsubstituted alkyl; R 5A2 and R 5A3 is a member independently selected from hydrogen and unsubstituted alkyl.
17. 17. The method of claim 16, wherein the fused azadecalin compound is (R)-(4a-ethoxymethyl-1-(4-fluorophenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1H,1,2,6-triaza-cyclopenta[b]naphthalene, also known as CORT 108297, having the formula [C5]
18. The method of any one of claims 1 to 9, wherein the SGRM is CORT108297 and the checkpoint inhibitor is an antibody effective against PD-1.
19. The method of any one of claims 1 to 9, wherein the SGRM is CORT108297 and the checkpoint inhibitor is an antibody effective against CTLA-4.
20. The method of any one of claims 1 to 9, wherein the SGRM is CORT108297 and the checkpoint inhibitor is an antibody effective against PD-L1.
21. The method of any one of claims 1 to 9, wherein the SGRM is CORT108297 and the checkpoint inhibitor is an antibody effective against PDL-2.
22. The method of any one of claims 1 to 9, wherein the SGRM is an octahydro-fused azadecalin compound having the formula: [C6] During the ceremony, R 1 is a heteroaryl ring having 5 to 6 ring members and 1 to 4 heteroatoms each independently selected from the group consisting of N, O, and S, each heteroaryl ring being independently selected from R 1a may be substituted with 1 to 4 groups selected from R 1a are each independently hydrogen, C 1-6Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, N-oxide, and C 3-8 cycloalkyl; Ring J is selected from the group consisting of aryl and heteroaryl rings having 5-6 ring members and 1-4 heteroatoms, each independently selected from the group consisting of N, O, and S; R 2 are each independently hydrogen, C 1-6 Alkyl, halogen, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl-C 1-6 Alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , S.R. 2a , S(O)R 2a , S(O) 2 R 2a , C 3-8 cycloalkyl, and C having 1 to 3 heteroatoms each independently selected from the group consisting of N, O, and S; 3-8 heterocycloalkyl; Alternatively, two R on adjacent ring atoms 2 The groups combine to form a heterocycloalkyl ring having 5-6 ring members and 1-3 heteroatoms each independently selected from the group consisting of N, O, and S, and the heterocycloalkyl ring is comprised of 1-3 R 2c may be substituted with a group; R 2a , R 2b , and R 2c are each independently hydrogen and C 1-6 selected from the group consisting of alkyl; R 3a are each independently a halogen; The subscript n is an integer from 0 to 3.
23. 23. The method of claim 22, wherein the octahydro-fused azadecalin SGRM is ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, also known as CORT125281, having the structure [C7]
24. The method of any one of claims 1 to 9, wherein the SGRM is CORT125281 and the checkpoint inhibitor is an antibody effective against PD-1.
25. The method of any one of claims 1 to 9, wherein the SGRM is CORT125281 and the checkpoint inhibitor is an antibody effective against CTLA-4.
26. The method of any one of claims 1 to 9, wherein the SGRM is CORT125281 and the checkpoint inhibitor is an antibody effective against PD-L1.
27. The method of any one of claims 1 to 9, wherein the SGRM is CORT125281 and the checkpoint inhibitor is an antibody effective against PDL-2.
28. A pharmaceutical composition for treating adrenocortical carcinoma comprising a selective glucocorticoid receptor modulator (SGRM) compound and an antibody checkpoint inhibitor effective against PD-1, CTLA-4, PDL-1, or PDL-2.
29. 29. The pharmaceutical composition of claim 28, wherein the SGRM is a compound selected from a heteroaryl ketone fused azadecalin SGRM, a fused azadecalin SGRM, and an octahydro fused azadecalin SGRM.
30. The pharmaceutical composition of claim 28 or claim 29, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PD-1.
31. 30. The pharmaceutical composition of claim 28 or claim 29, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against CTLA-4.
32. The pharmaceutical composition of claim 28 or 29, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PD-L1.
33. The pharmaceutical composition of claim 28 or claim 29, wherein the SGRM is relacorilant and the checkpoint inhibitor is an antibody effective against PDL-2.
34. 10. Any one of claims 1, 2 to 9, wherein the SGRM is a heteroaryl-ketone fused azadecalin compound (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-2-yl)methanone (referred to as "CORT122928") having the following structure: or the pharmaceutical composition of claim 28 or 29. [C8]
35. 30. The method of any one of claims 1, 2 to 9, or the pharmaceutical composition of claim 28 or 29, wherein the SGRM is the compound (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1-H-pyrazoloP,4-g)isoquinolin-4a-yl)(pyridin-2-yl)methanone (referred to as "CORT113176"), having the structure: [C9]
